<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.22a -->
    <!-- Field: Doc-Info; Name: Source; Value: 174390 12312017 20F.xfr; Date: 2018%2D03%2D19T16:05:54Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80130000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2016-03-31/ifrs-full" xmlns:AFMD="http://affimed.com/20171231">
    <link:schemaRef xlink:href="afmd-20171231.xsd" xlink:type="simple" />
    <xbrli:context id="From2017-01-01to2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_GermanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:GermanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_GermanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:GermanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_GermanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:GermanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_EuropeAreaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:EuropeAreaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_EuropeAreaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:EuropeAreaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_EuropeAreaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:EuropeAreaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_UnitedStatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:UnitedStatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_UnitedStatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:UnitedStatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_UnitedStatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:UnitedStatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_GermanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:GermanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_CzechRepublicMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:CzechRepublicMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_GermanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:GermanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_CzechRepublicMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">AFMD:CzechRepublicMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_AmphivenaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">AFMD:AmphivenaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_AmphivenaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">AFMD:AmphivenaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_AmphivenaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">AFMD:AmphivenaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_LeukemiaAndLymphomaSocietyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">AFMD:LeukemiaAndLymphomaSocietyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_LeukemiaAndLymphomaSocietyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">AFMD:LeukemiaAndLymphomaSocietyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_LeukemiaAndLymphomaSocietyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">AFMD:LeukemiaAndLymphomaSocietyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_AbCheckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">AFMD:AbCheckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_AbCheckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">AFMD:AbCheckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_AbCheckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">AFMD:AbCheckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_ThirdPartyServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:ThirdPartyServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_ThirdPartyServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:ThirdPartyServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_ThirdPartyServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:ThirdPartyServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_PersonnelExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:PersonnelExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_PersonnelExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:PersonnelExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_PersonnelExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:PersonnelExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_LegalConsultingAndPatentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:LegalConsultingAndPatentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_LegalConsultingAndPatentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:LegalConsultingAndPatentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_LegalConsultingAndPatentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:LegalConsultingAndPatentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_CostsOfMaterialsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:CostsOfMaterialsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_CostsOfMaterialsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:CostsOfMaterialsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_CostsOfMaterialsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:CostsOfMaterialsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_OperatingLeaseExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:OperatingLeaseExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_OperatingLeaseExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:OperatingLeaseExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_OperatingLeaseExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:OperatingLeaseExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_OtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:OtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_OtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:OtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_OtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:OtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_LegalConsultingAndAuditFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:LegalConsultingAndAuditFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_LegalConsultingAndAuditFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:LegalConsultingAndAuditFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_LegalConsultingAndAuditFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:LegalConsultingAndAuditFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_InterestPerceptiveLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:InterestPerceptiveLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_InterestPerceptiveLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:InterestPerceptiveLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_InterestPerceptiveLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:InterestPerceptiveLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_OtherFinanceCostPerceptiveLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:OtherFinanceCostPerceptiveLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_OtherFinanceCostPerceptiveLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:OtherFinanceCostPerceptiveLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_OtherFinanceCostPerceptiveLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:OtherFinanceCostPerceptiveLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_InterestSVBLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:InterestSVBLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_InterestSVBLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:InterestSVBLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_InterestSVBLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:InterestSVBLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_ForeignExchangeDifferencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:ForeignExchangeDifferencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_ForeignExchangeDifferencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:ForeignExchangeDifferencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_ForeignExchangeDifferencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:ForeignExchangeDifferencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_InterestCertificatesOfDepositMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:InterestCertificatesOfDepositMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_InterestCertificatesOfDepositMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:InterestCertificatesOfDepositMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_InterestCertificatesOfDepositMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:InterestCertificatesOfDepositMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_OtherFinanceIncomeFinanceCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:OtherFinanceIncomeFinanceCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_OtherFinanceIncomeFinanceCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:OtherFinanceIncomeFinanceCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_OtherFinanceIncomeFinanceCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfIncomeExpenseAxis">AFMD:OtherFinanceIncomeFinanceCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_ifrs-full_OtherAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_TradeAndOtherReceivablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">AFMD:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_TradeAndOtherReceivablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">AFMD:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_ResearchAndDevelopmentGrantsAndOtherGovernmentSubsidiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">AFMD:ResearchAndDevelopmentGrantsAndOtherGovernmentSubsidiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_ResearchAndDevelopmentGrantsAndOtherGovernmentSubsidiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">AFMD:ResearchAndDevelopmentGrantsAndOtherGovernmentSubsidiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_ValueAddedTaxReceivablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">AFMD:ValueAddedTaxReceivablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_ValueAddedTaxReceivablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">AFMD:ValueAddedTaxReceivablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_RefundingOfResearchAndDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">AFMD:RefundingOfResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_Esop2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">AFMD:Esop2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_Esop2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">AFMD:Esop2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_Esop2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">AFMD:Esop2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_Esop2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">AFMD:Esop2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_ThereofAssetsPledgedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">AFMD:ThereofAssetsPledgedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_ThereofAssetsPledgedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">AFMD:ThereofAssetsPledgedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_ifrs-full_NotLaterThanOneYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_ifrs-full_NotLaterThanOneYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_ThomasHechtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:ThomasHechtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_ThomasHechtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:ThomasHechtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_RichardSteadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:RichardSteadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_RichardSteadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:RichardSteadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_BemdtModigMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:BemdtModigMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_BemdtModigMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:BemdtModigMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_FerdinandVerdonckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:FerdinandVerdonckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_FerdinandVerdonckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:FerdinandVerdonckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_UlrichGrauMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:UlrichGrauMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_UlrichGrauMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:UlrichGrauMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_BernhardEhmerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:BernhardEhmerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_BernhardEhmerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:BernhardEhmerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_JensPeterMarschnerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:JensPeterMarschnerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_JensPeterMarschnerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:JensPeterMarschnerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_CZKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">AFMD:CZKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_CZKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">AFMD:CZKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_CZKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">AFMD:CZKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_CZKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">AFMD:CZKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_CZKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">AFMD:CZKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_CZKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">AFMD:CZKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_USDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">AFMD:USDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_USDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">AFMD:USDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_USDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">AFMD:USDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_USDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">AFMD:USDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_USDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">AFMD:USDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_USDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">AFMD:USDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_TemporaryDifferenceBorrowingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">AFMD:TemporaryDifferenceBorrowingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_TemporaryDifferenceBorrowingsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">AFMD:TemporaryDifferenceBorrowingsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_StandardAmendment1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">AFMD:StandardAmendment1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_StandardAmendment2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">AFMD:StandardAmendment2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_StandardAmendment3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">AFMD:StandardAmendment3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_StandardAmendment4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">AFMD:StandardAmendment4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_StandardAmendment5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">AFMD:StandardAmendment5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_StandardAmendment6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">AFMD:StandardAmendment6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_StandardAmendment7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">AFMD:StandardAmendment7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_StandardAmendment8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">AFMD:StandardAmendment8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_StandardAmendment9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">AFMD:StandardAmendment9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_GeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:GeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_GeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:GeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_GeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="AFMD:NatureOfExpensesAxis">AFMD:GeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_SupervisoryBoardDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:SupervisoryBoardDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_SupervisoryBoardDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:SupervisoryBoardDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_SupervisoryBoardDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001608390</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">AFMD:SupervisoryBoardDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EURPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:EUR</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Years">
      <xbrli:measure>utr:Y</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="CZKPEUR">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:CZK</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>iso4217:EUR</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="USDPEUR">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>iso4217:EUR</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2017-01-01to2017-12-31">Affimed N.V.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2017-01-01to2017-12-31">0001608390</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2017-01-01to2017-12-31">20-F</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2017-01-01to2017-12-31">2017-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2017-01-01to2017-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2017-01-01to2017-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2017-01-01to2017-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2017-01-01to2017-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2017-01-01to2017-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2017-01-01to2017-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2017-01-01to2017-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2017-01-01to2017-12-31">2017</dei:DocumentFiscalYearFocus>
    <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="From2017-01-01to2017-12-31" unitRef="EURPShares" decimals="INF">-.69</ifrs-full:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="From2016-01-01to2016-12-31" unitRef="EURPShares" decimals="INF">-0.97</ifrs-full:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="From2015-01-01to2015-12-31" unitRef="EURPShares" decimals="INF">-0.71</ifrs-full:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:ComprehensiveIncome contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-30223000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-32216000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-20239000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ProfitLoss contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-30223000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-32216000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-20239000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="From2017-01-01to2017-12-31_ifrs-full_RetainedEarningsMember" unitRef="EUR" decimals="-3">-30223000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="From2016-01-01to2016-12-31_ifrs-full_RetainedEarningsMember" unitRef="EUR" decimals="-3">-32216000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="From2015-01-01to2015-12-31_ifrs-full_RetainedEarningsMember" unitRef="EUR" decimals="-3">-20239000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossBeforeTax contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-30243000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-32274000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-20239000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:FinanceIncome contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-2983000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-230000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">1104000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2017-01-01to2017-12-31_custom_InterestPerceptiveLoanAgreementMember" unitRef="EUR" decimals="-3">0</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2016-01-01to2016-12-31_custom_InterestPerceptiveLoanAgreementMember" unitRef="EUR" decimals="-3">-762000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2015-01-01to2015-12-31_custom_InterestPerceptiveLoanAgreementMember" unitRef="EUR" decimals="-3">-703000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2017-01-01to2017-12-31_custom_OtherFinanceCostPerceptiveLoanAgreementMember" unitRef="EUR" decimals="-3">0</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2016-01-01to2016-12-31_custom_OtherFinanceCostPerceptiveLoanAgreementMember" unitRef="EUR" decimals="-3">-242000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2015-01-01to2015-12-31_custom_OtherFinanceCostPerceptiveLoanAgreementMember" unitRef="EUR" decimals="-3">0</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2017-01-01to2017-12-31_custom_InterestSVBLoanAgreementMember" unitRef="EUR" decimals="-3">-690000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2016-01-01to2016-12-31_custom_InterestSVBLoanAgreementMember" unitRef="EUR" decimals="-3">-41000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2015-01-01to2015-12-31_custom_InterestSVBLoanAgreementMember" unitRef="EUR" decimals="-3">0</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2017-01-01to2017-12-31_custom_ForeignExchangeDifferencesMember" unitRef="EUR" decimals="-3">-2378000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2016-01-01to2016-12-31_custom_ForeignExchangeDifferencesMember" unitRef="EUR" decimals="-3">691000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2015-01-01to2015-12-31_custom_ForeignExchangeDifferencesMember" unitRef="EUR" decimals="-3">1808000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2017-01-01to2017-12-31_custom_InterestCertificatesOfDepositMember" unitRef="EUR" decimals="-3">77000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2016-01-01to2016-12-31_custom_InterestCertificatesOfDepositMember" unitRef="EUR" decimals="-3">122000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2015-01-01to2015-12-31_custom_InterestCertificatesOfDepositMember" unitRef="EUR" decimals="-3">0</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2017-01-01to2017-12-31_custom_OtherFinanceIncomeFinanceCostsMember" unitRef="EUR" decimals="-3">8000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2016-01-01to2016-12-31_custom_OtherFinanceIncomeFinanceCostsMember" unitRef="EUR" decimals="-3">2000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="From2015-01-01to2015-12-31_custom_OtherFinanceIncomeFinanceCostsMember" unitRef="EUR" decimals="-3">-1000</ifrs-full:FinanceIncome>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-27260000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-32044000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-21343000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:OtherIncome contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">205000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">145000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">651000</ifrs-full:OtherIncome>
    <ifrs-full:Revenue contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">2010000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">6314000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">7562000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="From2017-01-01to2017-12-31_custom_GermanyMember" unitRef="EUR" decimals="-3">80000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="From2016-01-01to2016-12-31_custom_GermanyMember" unitRef="EUR" decimals="-3">6000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="From2015-01-01to2015-12-31_custom_GermanyMember" unitRef="EUR" decimals="-3">125000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="From2017-01-01to2017-12-31_custom_EuropeAreaMember" unitRef="EUR" decimals="-3">1236000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="From2016-01-01to2016-12-31_custom_EuropeAreaMember" unitRef="EUR" decimals="-3">1397000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="From2015-01-01to2015-12-31_custom_EuropeAreaMember" unitRef="EUR" decimals="-3">711000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="From2017-01-01to2017-12-31_custom_UnitedStatesMember" unitRef="EUR" decimals="-3">694000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="From2016-01-01to2016-12-31_custom_UnitedStatesMember" unitRef="EUR" decimals="-3">4911000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="From2015-01-01to2015-12-31_custom_UnitedStatesMember" unitRef="EUR" decimals="-3">6725000</ifrs-full:Revenue>
    <ifrs-full:NoncurrentAssets contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">1178000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">877000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="AsOf2017-12-31_custom_GermanyMember" unitRef="EUR" decimals="-3">957000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="AsOf2017-12-31_custom_CzechRepublicMember" unitRef="EUR" decimals="-3">221000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="AsOf2016-12-31_custom_GermanyMember" unitRef="EUR" decimals="-3">618000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="AsOf2016-12-31_custom_CzechRepublicMember" unitRef="EUR" decimals="-3">259000</ifrs-full:NoncurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">1113000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">822000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="AsOf2017-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">891000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="AsOf2016-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">542000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">65000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">55000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:Inventories contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">241000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">197000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="AsOf2017-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">219000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="AsOf2016-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">177000</ifrs-full:Inventories>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">1102000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">2255000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="AsOf2017-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">328000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="AsOf2016-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">1217000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:OtherAssets contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">800000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">516000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="AsOf2017-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">292000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="AsOf2016-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">0</ifrs-full:OtherAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">9487000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">39837000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">35407000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2015-12-31" unitRef="EUR" decimals="-3">76740000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2014-12-31" unitRef="EUR" decimals="-3">39725000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2017-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">38726000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2016-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">34674000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">41980000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">47862000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">43158000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">48739000</ifrs-full:Assets>
    <ifrs-full:Equity contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">31579000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">38751000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2015-12-31" unitRef="EUR" decimals="-3">67274000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2014-12-31" unitRef="EUR" decimals="-3">31795000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2016-12-31_ifrs-full_IssuedCapitalMember" unitRef="EUR" decimals="-3">333000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2017-12-31_ifrs-full_IssuedCapitalMember" unitRef="EUR" decimals="-3">468000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2015-12-31_ifrs-full_IssuedCapitalMember" unitRef="EUR" decimals="-3">333000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2014-12-31_ifrs-full_IssuedCapitalMember" unitRef="EUR" decimals="-3">240000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2016-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">190862000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2017-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">213778000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2015-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">187169000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2014-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">131544000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2016-12-31_ifrs-full_RetainedEarningsMember" unitRef="EUR" decimals="-3">-152444000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2017-12-31_ifrs-full_RetainedEarningsMember" unitRef="EUR" decimals="-3">-182667000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2015-12-31_ifrs-full_RetainedEarningsMember" unitRef="EUR" decimals="-3">-120228000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2014-12-31_ifrs-full_RetainedEarningsMember" unitRef="EUR" decimals="-3">-99989000</ifrs-full:Equity>
    <ifrs-full:RetainedEarnings contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">-182667000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">-152444000</ifrs-full:RetainedEarnings>
    <ifrs-full:OtherReserves contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">213778000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">190862000</ifrs-full:OtherReserves>
    <ifrs-full:IssuedCapital contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">468000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">333000</ifrs-full:IssuedCapital>
    <ifrs-full:NoncurrentLiabilities contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">4086000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">3617000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:LongtermBorrowings contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">4086000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">3617000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentLiabilities contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">7493000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">6371000</ifrs-full:CurrentLiabilities>
    <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">230000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
    <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">75000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
    <ifrs-full:Borrowings contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">3083000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">973000</ifrs-full:Borrowings>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">4180000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">5323000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:EquityAndLiabilities contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">43158000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">48739000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">2983000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">230000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-1104000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">1943000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">3545000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">2220000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-19000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">351000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">369000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">336000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-20000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-58000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-24985000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-28130000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-18787000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">21489000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">30180000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">22008000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31_custom_ThirdPartyServicesMember" unitRef="EUR" decimals="-3">12299000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31_custom_ThirdPartyServicesMember" unitRef="EUR" decimals="-3">20170000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31_custom_ThirdPartyServicesMember" unitRef="EUR" decimals="-3">15386000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31_custom_PersonnelExpensesMember" unitRef="EUR" decimals="-3">5639000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31_custom_PersonnelExpensesMember" unitRef="EUR" decimals="-3">6648000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31_custom_PersonnelExpensesMember" unitRef="EUR" decimals="-3">3637000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31_custom_LegalConsultingAndPatentExpensesMember" unitRef="EUR" decimals="-3">890000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31_custom_LegalConsultingAndPatentExpensesMember" unitRef="EUR" decimals="-3">758000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31_custom_LegalConsultingAndPatentExpensesMember" unitRef="EUR" decimals="-3">902000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31_custom_CostsOfMaterialsMember" unitRef="EUR" decimals="-3">994000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31_custom_CostsOfMaterialsMember" unitRef="EUR" decimals="-3">1028000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31_custom_CostsOfMaterialsMember" unitRef="EUR" decimals="-3">902000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31_ifrs-full_AccumulatedDepreciationAndAmortisationMember" unitRef="EUR" decimals="-3">309000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31_ifrs-full_AccumulatedDepreciationAndAmortisationMember" unitRef="EUR" decimals="-3">322000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31_ifrs-full_AccumulatedDepreciationAndAmortisationMember" unitRef="EUR" decimals="-3">308000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31_custom_OperatingLeaseExpensesMember" unitRef="EUR" decimals="-3">345000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31_custom_OperatingLeaseExpensesMember" unitRef="EUR" decimals="-3">297000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31_custom_OperatingLeaseExpensesMember" unitRef="EUR" decimals="-3">267000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31_custom_OtherExpensesMember" unitRef="EUR" decimals="-3">1013000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31_custom_OtherExpensesMember" unitRef="EUR" decimals="-3">957000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31_custom_OtherExpensesMember" unitRef="EUR" decimals="-3">606000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">7986000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">8323000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">7548000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-12-31_custom_PersonnelExpensesMember" unitRef="EUR" decimals="-3">4521000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-12-31_custom_PersonnelExpensesMember" unitRef="EUR" decimals="-3">4729000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31_custom_PersonnelExpensesMember" unitRef="EUR" decimals="-3">3658000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-12-31_custom_OperatingLeaseExpensesMember" unitRef="EUR" decimals="-3">126000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-12-31_custom_OperatingLeaseExpensesMember" unitRef="EUR" decimals="-3">111000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31_custom_OperatingLeaseExpensesMember" unitRef="EUR" decimals="-3">89000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-12-31_custom_OtherExpensesMember" unitRef="EUR" decimals="-3">1394000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-12-31_custom_OtherExpensesMember" unitRef="EUR" decimals="-3">1273000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31_custom_OtherExpensesMember" unitRef="EUR" decimals="-3">1333000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-12-31_custom_LegalConsultingAndAuditFeesMember" unitRef="EUR" decimals="-3">1945000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-12-31_custom_LegalConsultingAndAuditFeesMember" unitRef="EUR" decimals="-3">2210000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31_custom_LegalConsultingAndAuditFeesMember" unitRef="EUR" decimals="-3">2468000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-20000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-58000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">1140000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-1311000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">24000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-44000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">31000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-29000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-399000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-64000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-452000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-1018000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-2177000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">1253000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-25549000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-32127000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-18535000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">106000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">102000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">10000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-25306000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-31651000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-17991000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">349000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">578000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">554000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">22063000</ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets>
    <ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">18147000</ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets>
    <ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">35000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">8050000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-9149000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-277000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">43000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">21000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">28000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">625000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">238000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">249000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfAvailableforsaleFinancialAssets contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">13084000</ifrs-full:PurchaseOfAvailableforsaleFinancialAssets>
    <ifrs-full:PurchaseOfAvailableforsaleFinancialAssets contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">27037000</ifrs-full:PurchaseOfAvailableforsaleFinancialAssets>
    <ifrs-full:PurchaseOfAvailableforsaleFinancialAssets contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:PurchaseOfAvailableforsaleFinancialAssets>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">23123000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">6000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">56615000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">23797000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-236000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">53498000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">2500000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">5000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ShareIssueRelatedCost contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-1648000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-3117000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:BorrowingCostsRecognisedAsExpense contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-11000</ifrs-full:BorrowingCostsRecognisedAsExpense>
    <ifrs-full:BorrowingCostsRecognisedAsExpense contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-105000</ifrs-full:BorrowingCostsRecognisedAsExpense>
    <ifrs-full:BorrowingCostsRecognisedAsExpense contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:BorrowingCostsRecognisedAsExpense>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">167000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">5137000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">6297000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-41512000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">34686000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">46791352</dei:EntityCommonStockSharesOutstanding>
    <ifrs-full:IssueOfEquity contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">21057000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="From2016-01-01to2016-12-31" unitRef="EUR" id="Foot-00-0" decimals="-3">6000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">52554000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="From2017-01-01to2017-12-31_ifrs-full_IssuedCapitalMember" unitRef="EUR" decimals="-3">135000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="From2016-01-01to2016-12-31_ifrs-full_IssuedCapitalMember" unitRef="EUR" decimals="-3">0</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="From2015-01-01to2015-12-31_ifrs-full_IssuedCapitalMember" unitRef="EUR" decimals="-3">91000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="From2017-01-01to2017-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">20922000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="From2016-01-01to2016-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">6000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="From2015-01-01to2015-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">52463000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">944000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="From2015-01-01to2015-12-31_ifrs-full_IssuedCapitalMember" unitRef="EUR" decimals="-3">2000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="From2015-01-01to2015-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">942000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">1943000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">3545000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">2220000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="From2017-01-01to2017-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">1943000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="From2016-01-01to2016-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">3545000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="From2015-01-01to2015-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">2220000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IssueOfConvertibleInstruments contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">51000</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:IssueOfConvertibleInstruments contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">142000</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:IssueOfConvertibleInstruments contextRef="From2017-01-01to2017-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">51000</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:IssueOfConvertibleInstruments contextRef="From2016-01-01to2016-12-31_ifrs-full_OtherReservesMember" unitRef="EUR" decimals="-3">142000</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment1Member" id="Foot-01-0">2018-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
    <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment2Member" id="Foot-01-1">2018-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
    <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment3Member" id="Foot-01-2">2019-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
    <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment4Member" id="Foot-01-3">2018-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
    <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment5Member" id="Foot-01-4">2018-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
    <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment6Member" id="Foot-01-5">2018-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
    <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment7Member" id="Foot-01-6">2019-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
    <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment8Member" id="Foot-01-7">2019-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
    <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment9Member" id="Foot-01-8">2019-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
    <ifrs-full:RevenueFromRenderingOfServices contextRef="From2017-01-01to2017-12-31_custom_AmphivenaMember" unitRef="EUR" decimals="-3">200000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices contextRef="From2016-01-01to2016-12-31_custom_AmphivenaMember" unitRef="EUR" decimals="-3">3400000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices contextRef="From2015-01-01to2015-12-31_custom_AmphivenaMember" unitRef="EUR" decimals="-3">4800000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices contextRef="From2017-01-01to2017-12-31_custom_LeukemiaAndLymphomaSocietyMember" unitRef="EUR" decimals="-3">200000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices contextRef="From2016-01-01to2016-12-31_custom_LeukemiaAndLymphomaSocietyMember" unitRef="EUR" decimals="-3">400000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices contextRef="From2015-01-01to2015-12-31_custom_LeukemiaAndLymphomaSocietyMember" unitRef="EUR" decimals="-3">1600000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices contextRef="From2017-01-01to2017-12-31_custom_AbCheckMember" unitRef="EUR" decimals="-3">1600000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices contextRef="From2016-01-01to2016-12-31_custom_AbCheckMember" unitRef="EUR" decimals="-3">2400000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices contextRef="From2015-01-01to2015-12-31_custom_AbCheckMember" unitRef="EUR" decimals="-3">1100000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">195000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">171000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">716000</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:WagesAndSalaries contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">7475000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">7445000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">5066000</ifrs-full:WagesAndSalaries>
    <ifrs-full:SocialSecurityContributions contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">931000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">807000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">583000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:EmployeeBenefitsExpense contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">8406000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">8252000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">5649000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployerContributions contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">438000</ifrs-full:EmployerContributions>
    <ifrs-full:EmployerContributions contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">362000</ifrs-full:EmployerContributions>
    <ifrs-full:EmployerContributions contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">269000</ifrs-full:EmployerContributions>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">16000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">154000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">163000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-82000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-39000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-165000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">9020000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">9626000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">6036000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <AFMD:TaxEffectDueToImpairmentOfDeferredTaxAssets contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-9036000</AFMD:TaxEffectDueToImpairmentOfDeferredTaxAssets>
    <AFMD:TaxEffectDueToImpairmentOfDeferredTaxAssets contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-8747000</AFMD:TaxEffectDueToImpairmentOfDeferredTaxAssets>
    <AFMD:TaxEffectDueToImpairmentOfDeferredTaxAssets contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">-6251000</AFMD:TaxEffectDueToImpairmentOfDeferredTaxAssets>
    <AFMD:TaxEffectOfPermanentDifferences contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-93000</AFMD:TaxEffectOfPermanentDifferences>
    <AFMD:TaxEffectOfPermanentDifferences contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">-948000</AFMD:TaxEffectOfPermanentDifferences>
    <AFMD:TaxEffectOfPermanentDifferences contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">199000</AFMD:TaxEffectOfPermanentDifferences>
    <AFMD:TaxEffectOfLocalTaxRates contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">195000</AFMD:TaxEffectOfLocalTaxRates>
    <AFMD:TaxEffectOfLocalTaxRates contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">12000</AFMD:TaxEffectOfLocalTaxRates>
    <AFMD:TaxEffectOfLocalTaxRates contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">18000</AFMD:TaxEffectOfLocalTaxRates>
    <ifrs-full:DeferredTaxLiabilities contextRef="AsOf2016-12-31_ifrs-full_OtherAssetsMember" unitRef="EUR" decimals="-3">121000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="AsOf2017-12-31_custom_TemporaryDifferenceBorrowingsMember" unitRef="EUR" decimals="-3">152000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities contextRef="AsOf2016-12-31_custom_TemporaryDifferenceBorrowingsMember" unitRef="EUR" decimals="-3">129000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxAssets contextRef="AsOf2017-12-31_custom_TradeAndOtherReceivablesMember" unitRef="EUR" decimals="-3">259000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="AsOf2016-12-31_custom_TradeAndOtherReceivablesMember" unitRef="EUR" decimals="-3">292000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="AsOf2017-12-31_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" unitRef="EUR" decimals="-3">405000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="AsOf2016-12-31_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" unitRef="EUR" decimals="-3">49000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:TradeReceivables contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">580000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">970000</ifrs-full:TradeReceivables>
    <AFMD:OverdueTradeReceivables contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">260000</AFMD:OverdueTradeReceivables>
    <AFMD:OverdueTradeReceivables contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">219000</AFMD:OverdueTradeReceivables>
    <ifrs-full:OtherReceivables contextRef="AsOf2017-12-31_custom_ResearchAndDevelopmentGrantsAndOtherGovernmentSubsidiesMember" unitRef="EUR" decimals="-3">20000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="AsOf2016-12-31_custom_ResearchAndDevelopmentGrantsAndOtherGovernmentSubsidiesMember" unitRef="EUR" decimals="-3">14000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="AsOf2017-12-31_custom_ValueAddedTaxReceivablesMember" unitRef="EUR" decimals="-3">186000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="AsOf2016-12-31_custom_ValueAddedTaxReceivablesMember" unitRef="EUR" decimals="-3">642000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="AsOf2016-12-31_custom_RefundingOfResearchAndDevelopmentCostsMember" unitRef="EUR" decimals="-3">385000</ifrs-full:OtherReceivables>
    <ifrs-full:NumberOfSharesOutstanding contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">46791352</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">33262745</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare contextRef="AsOf2017-12-31" unitRef="EURPShares" decimals="INF">.01</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare contextRef="AsOf2016-12-31" unitRef="EURPShares" decimals="INF">.01</ifrs-full:ParValuePerShare>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="AsOf2017-12-31" unitRef="EUR" decimals="2">1.1</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="AsOf2016-12-31" unitRef="EUR" decimals="2">1.99</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePrice contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="2">2</ifrs-full:WeightedAverageSharePrice>
    <ifrs-full:WeightedAverageSharePrice contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="2">3.55</ifrs-full:WeightedAverageSharePrice>
    <ifrs-full:ExercisePriceShareOptionsGranted contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="2">2.03</ifrs-full:ExercisePriceShareOptionsGranted>
    <ifrs-full:ExercisePriceShareOptionsGranted contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="2">3.57</ifrs-full:ExercisePriceShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="From2017-01-01to2017-12-31" unitRef="Percent" decimals="INF">0.7000</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="From2016-01-01to2016-12-31" unitRef="Percent" decimals="INF">0.6900</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendShareOptionsGranted contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="2">0</ifrs-full:ExpectedDividendShareOptionsGranted>
    <ifrs-full:ExpectedDividendShareOptionsGranted contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="2">0</ifrs-full:ExpectedDividendShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="From2017-01-01to2017-12-31" unitRef="Percent" decimals="INF">-.0023</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="From2016-01-01to2016-12-31" unitRef="Percent" decimals="INF">-.0032</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="From2017-01-01to2017-12-31" unitRef="Years" decimals="INF">5.90</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="From2016-01-01to2016-12-31" unitRef="Years" decimals="INF">5.90</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="AsOf2017-12-31_custom_Esop2014Member" unitRef="Shares" decimals="INF">4080868</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="AsOf2016-12-31_custom_Esop2014Member" unitRef="Shares" decimals="INF">3044345</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="From2017-01-01to2017-12-31_custom_Esop2014Member" unitRef="Shares" decimals="INF">2001264</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="From2016-01-01to2016-12-31_custom_Esop2014Member" unitRef="Shares" decimals="INF">952458</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="AsOf2017-12-31_custom_Esop2014Member" unitRef="Years" decimals="INF">8.4</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="AsOf2016-12-31_custom_Esop2014Member" unitRef="Years" decimals="INF">8.9</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
    <ifrs-full:InterestCostsIncurred contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">762000</ifrs-full:InterestCostsIncurred>
    <ifrs-full:InterestCostsIncurred contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">703000</ifrs-full:InterestCostsIncurred>
    <ifrs-full:NetForeignExchangeLoss contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">86000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:NetForeignExchangeLoss contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">527000</ifrs-full:NetForeignExchangeLoss>
    <ifrs-full:FinancialAssets contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">9487000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="AsOf2017-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">0</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="AsOf2016-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">9487000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">43093000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
    <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">48684000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
    <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities contextRef="AsOf2017-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">40457000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
    <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities contextRef="AsOf2016-12-31_custom_ThereofAssetsPledgedMember" unitRef="EUR" decimals="-3">46096000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
    <ifrs-full:TradeAndOtherPayables contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">3380000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">4506000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:OtherPayables contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">514000</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">471000</ifrs-full:OtherPayables>
    <ifrs-full:WeightedAverageShares contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">43746073</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">33259505</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="From2015-01-01to2015-12-31" unitRef="Shares" decimals="INF">28477438</ifrs-full:WeightedAverageShares>
    <ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">833000</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
    <ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">1241000</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
    <ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="AsOf2017-12-31_ifrs-full_NotLaterThanOneYearMember" unitRef="EUR" decimals="-3">470000</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
    <ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="AsOf2016-12-31_ifrs-full_NotLaterThanOneYearMember" unitRef="EUR" decimals="-3">700000</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
    <ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="AsOf2017-12-31_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="EUR" decimals="-3">363000</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
    <ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="AsOf2016-12-31_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="EUR" decimals="-3">541000</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
    <ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">472000</ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense>
    <ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">409000</ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense>
    <ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">356000</ifrs-full:LeaseAndSubleasePaymentsRecognisedAsExpense>
    <ifrs-full:OtherFeeAndCommissionExpense contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">174000</ifrs-full:OtherFeeAndCommissionExpense>
    <ifrs-full:OtherFeeAndCommissionExpense contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">405000</ifrs-full:OtherFeeAndCommissionExpense>
    <ifrs-full:OtherFeeAndCommissionExpense contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">278000</ifrs-full:OtherFeeAndCommissionExpense>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">1538000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">1879000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">1633000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">430000</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">1379000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">2292000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">1474000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">2917000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">4601000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">3107000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2017-01-01to2017-12-31_custom_ThomasHechtMember" unitRef="EUR" decimals="-3">19000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2016-01-01to2016-12-31_custom_ThomasHechtMember" unitRef="EUR" decimals="-3">23000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2017-01-01to2017-12-31_custom_RichardSteadMember" unitRef="EUR" decimals="-3">12000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2016-01-01to2016-12-31_custom_RichardSteadMember" unitRef="EUR" decimals="-3">14000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2017-01-01to2017-12-31_custom_BemdtModigMember" unitRef="EUR" decimals="-3">9000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2016-01-01to2016-12-31_custom_BemdtModigMember" unitRef="EUR" decimals="-3">8000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2017-01-01to2017-12-31_custom_FerdinandVerdonckMember" unitRef="EUR" decimals="-3">10000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2016-01-01to2016-12-31_custom_FerdinandVerdonckMember" unitRef="EUR" decimals="-3">10000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2017-01-01to2017-12-31_custom_UlrichGrauMember" unitRef="EUR" decimals="-3">17000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2016-01-01to2016-12-31_custom_UlrichGrauMember" unitRef="EUR" decimals="-3">17000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2017-01-01to2017-12-31_custom_BernhardEhmerMember" unitRef="EUR" decimals="-3">10000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2016-01-01to2016-12-31_custom_BernhardEhmerMember" unitRef="EUR" decimals="-3">11000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2017-01-01to2017-12-31_custom_JensPeterMarschnerMember" unitRef="EUR" decimals="-3">0</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="From2016-01-01to2016-12-31_custom_JensPeterMarschnerMember" unitRef="EUR" decimals="-3">2000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:MaximumExposureToCreditRisk contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">41200000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">47200000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:AverageForeignExchangeRate contextRef="From2017-01-01to2017-12-31_custom_CZKMember" unitRef="CZKPEUR" decimals="INF">.03799</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate contextRef="From2016-01-01to2016-12-31_custom_CZKMember" unitRef="CZKPEUR" decimals="INF">.03699</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate contextRef="From2015-01-01to2015-12-31_custom_CZKMember" unitRef="CZKPEUR" decimals="INF">.03666</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate contextRef="From2017-01-01to2017-12-31_custom_USDMember" unitRef="USDPEUR" decimals="INF">.88519</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate contextRef="From2016-01-01to2016-12-31_custom_USDMember" unitRef="USDPEUR" decimals="INF">.90404</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate contextRef="From2015-01-01to2015-12-31_custom_USDMember" unitRef="USDPEUR" decimals="INF">.9019</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate contextRef="AsOf2017-12-31_custom_CZKMember" unitRef="CZKPEUR" decimals="INF">.03916</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate contextRef="AsOf2016-12-31_custom_CZKMember" unitRef="CZKPEUR" decimals="INF">.03701</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate contextRef="AsOf2015-12-31_custom_CZKMember" unitRef="CZKPEUR" decimals="INF">.03701</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate contextRef="AsOf2017-12-31_custom_USDMember" unitRef="USDPEUR" decimals="INF">.83382</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate contextRef="AsOf2016-12-31_custom_USDMember" unitRef="USDPEUR" decimals="INF">.94868</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate contextRef="AsOf2015-12-31_custom_USDMember" unitRef="USDPEUR" decimals="INF">.91853</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">296000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">0</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">-1867000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">179000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">2329000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Affimed N.V. is a Dutch company with limited&#13;liability (naamloze vennootschap) and has its corporate seat in Amsterdam, the Netherlands.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The consolidated financial statements are&#13;comprised of Affimed N.V, and its controlled (and wholly owned) subsidiaries Affimed GmbH, Heidelberg, Germany, AbCheck s.r.o.,&#13;Plzen, Czech Republic and Affimed Inc., Delaware, USA (together &amp;#8220;Affimed&amp;#8221; or the &amp;#8220;Company&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Affimed is a clinical-stage biopharmaceutical&#13;company focused on discovering and developing highly targeted cancer immunotherapies. The Company&amp;#8217;s product candidates are&#13;developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the&#13;body&amp;#8217;s own immune defenses to fight tumor cells. Affimed has own research and development programs and collaborations, where&#13;the Company is performing research services for third parties.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Statement of compliance&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements&#13;have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards&#13;Board (IFRS).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements&#13;were authorized for issuance by the management board on March 16, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of measurement&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements&#13;have been prepared on the historical cost basis except for financial instruments measured at fair value (see note 13) and monetary&#13;assets and liabilities denominated in foreign currencies, which are translated at period-end exchange rates. The Company did not&#13;opt for a valuation of liabilities at fair value through profit or loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Consolidation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company controls an entity when&#13;it has power over the investee, is exposed to, or has rights to, variable returns from its involvement with the entity and has&#13;the ability to affect those returns through its power over the entity. A subsidiary is consolidated from the date on which control&#13;is obtained by the Company. It is de-consolidated from the date control ceases.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Intercompany transactions, balances&#13;and unrealized gains on transactions between group companies are eliminated.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Functional and presentation currency&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements&#13;are presented in euro, which is also the subsidiaries&amp;#8217; functional currency. All financial information presented in euro has&#13;been rounded to the nearest thousand (abbreviated &amp;#8364;) or million (abbreviated &amp;#8364; million).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Presentation of consolidated statements&#13;of comprehensive loss&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a clinical-stage biopharmaceutical&#13;company with a primary focus on research and development activities, cost of sales and gross profit are not considered meaningful&#13;measures for Affimed and therefore are not presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Foreign currency transactions&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Transactions denominated in currencies&#13;other than the euro are translated at exchange rates at the date of the transaction. Monetary assets and liabilities denominated&#13;in currencies other than the euro are translated at the exchange rate at the date of the consolidated statement of financial position.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The foreign currency gain or loss on&#13;monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for&#13;effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at&#13;the end of the reporting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Foreign currency gains or losses that&#13;relate to borrowings, cash and cash equivalents and financial assets are presented in the statement of comprehensive loss within&#13;&amp;#8216;Finance income / (costs) - net&amp;#8217;. All other foreign exchange gains and losses are presented in the statement of comprehensive&#13;loss within &amp;#8216;Other income &amp;#8211; net&amp;#8217;.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accounting policies set out below have&#13;been applied consistently to all periods presented in these consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provides research and development&#13;services to third parties based on both Company and third party owned intellectual property. Such services are performed on a &amp;#8220;best&#13;efforts&amp;#8221; basis without a guarantee of technological or commercial success. For some research programs, Affimed has entered&#13;into collaborations with other companies that provide the Company with funding or other resources such as access to technologies.&#13;From time to time, the Company also licenses its intellectual property to third parties who use it to develop product candidates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Collaboration and license agreements are&#13;evaluated to determine whether they involve multiple elements that can be considered separate units of accounting. To date, the&#13;Company has not licensed or sold its intellectual property without continuing involvement by providing the related research and&#13;development services. Accordingly, the results under the Company&amp;#8217;s collaboration and license agreements have not qualified&#13;as separate units of accounting.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue from collaborative or other research&#13;service agreements is recognized according to the stage of completion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Milestone payments are contingent upon&#13;the achievement of contractually stipulated targets. The achievement of these targets or milestones depends largely on meeting&#13;specific requirements laid out in the respective agreement. Consideration that is contingent upon achievement of a milestone is&#13;recognized in its entirety as revenue in the period in which the milestone is achieved, but only if the consideration earned from&#13;the achievement of a milestone meets all the criteria for the milestone to be considered substantive at the inception of the agreement.&#13;For a milestone to be considered substantive, the consideration earned by achieving the milestone must (i) be commensurate with&#13;the Company&amp;#8217;s performance to achieve the milestone, (ii) relate solely to past performance, and (iii) be reasonable relative&#13;to all results and payment terms subject to the respective agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Non-refundable upfront research funding&#13;that generally has no stand-alone value to the customer and requires continuing involvement in the form of research and development&#13;services or other efforts by the Company is recognized as revenue ratably over the term of the service agreement which is the period&#13;of performance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Research and development&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Costs incurred related to research activities&#13;are expensed in the period incurred. Costs incurred on development projects are recognized as intangible assets beginning on the&#13;date it can be established that it is probable that future economic benefits attributable to the asset will flow to the Company&#13;considering its technological and commercial feasibility. Given the current stage of the development of the Company&amp;#8217;s product&#13;candidates and technologies, no development expenditures have yet been capitalized. Intellectual property-related costs for patents&#13;are part of the expenditure for the research and development projects. Therefore, registration costs for patents are expensed when&#13;incurred as long as the research and development project concerned does not meet the criteria for capitalization.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Employee benefits&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(i)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Short-term employee benefits&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Short-term employee benefit obligations&#13;are measured on an undiscounted basis and are expensed as the related service is provided.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A liability is recognized for the amount&#13;expected to be paid under a short-term cash bonus, if (a) the Company has a present legal or constructive obligation to pay this&#13;amount as a result of past service provided by the employee, and (b) the obligation can be estimated reliably.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Share-based payment transactions&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s share-based payment&#13;awards outstanding as of December 31, 2016 and 2017, are classified as equity-settled share-based plans. The fair value of share-based&#13;equity-settled awards granted to employees is measured at grant date and compensation cost is recognized over the vesting period&#13;with a corresponding increase in equity. Share-based payment awards with non-employees are measured and recognized when services&#13;are received. Fair value is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based&#13;on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns,&#13;dividends, the risk-free interest rate and the time to maturity of the option. The number of stock options expected to vest is&#13;estimated at each measurement date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Government grants&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company receives certain government&#13;grants that support its research effort in specific projects. These grants generally provide for reimbursement of approved costs&#13;incurred as defined in the respective grants. Income in respect of grants also includes contributions towards the costs of research&#13;and development. Income is recognized when costs under each grant are incurred in accordance with the terms and conditions of the&#13;grant and the collectability of the receivable is reasonably assured.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Government grants relating to costs are&#13;deferred and recognized in the income statement over the period necessary to match them with the costs they are intended to compensate.&#13;When the cash in relation to recognized government grants is not yet received the amount is included as a receivable on the statement&#13;of financial position.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes income from government&#13;grants under &amp;#8216;Other income - net&amp;#8217; in the consolidated statement of comprehensive loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Lease payments&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Payments made under operating leases are&#13;recognized in profit or loss on a straight-line basis over the term of the lease.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Finance income and finance costs&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Finance income comprises interest income&#13;from interest bearing bank deposits. Interest income is recognized as it accrues using the effective interest method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Finance costs comprise interest expense&#13;on borrowings and, in 2016, includes losses from early extinguishment of debt.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Financial instruments&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A financial instrument is any contract&#13;that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(i)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Non-derivative financial assets&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s non-derivative financial&#13;assets include trade and other receivables, cash and cash equivalents and, in 2016, certificates of deposit at banks with original&#13;maturities of more than three months.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Loans and receivables are non-derivative&#13;financial assets with fixed or determinable payments that are not quoted in an active market. They are included in current assets&#13;and are subsequently carried at amortized cost using the effective interest method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents comprise cash&#13;balances and call deposits with original maturities of three months or less.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Non-derivative financial liabilities&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0 0 0 28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s classes of financial&#13;liabilities are borrowings and trade and other payables. The Company initially recognizes non-derivative financial liabilities&#13;on the date that they are originated and measures them at amortized cost using the effective interest rate method. The Company&#13;derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(iii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Compound financial instruments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company entered into certain loan agreements&#13;pursuant to which it issued warrants to purchase common shares of the Company at the option of the respective holders (see note&#13;17). The number of shares to be issued does not vary with changes in their fair value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The liability component of the loans was&#13;recognized initially at the fair value of a similar liability without a warrant. The equity component was recognized initially&#13;at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component.&#13;Subsequent to initial recognition, the liability component is measured at amortized cost using the effective interest method. The&#13;equity component is not re-measured subsequent to initial recognition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2017, the Company entered into a convertible&#13;note agreement (see note 13). The Company designated the combined contract consisting of the loan component and the conversion&#13;feature embedded in the loan agreement at fair value through profit and loss and recognizes changes of fair value re-measured on&#13;a recurring basis in &amp;#8216;Finance income / (costs) &amp;#8211; net.&amp;#8217;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(iv)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Derivatives&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company acquired warrants to purchase&#13;common shares of Amphivena Therapeutics Inc. (&amp;#8220;Amphivena&amp;#8221;) at a specified price (see note 13). Initially, the warrants&#13;were recognized at fair value. Subsequently the fair value is re-measured on a recurring basis with changes recognized in &amp;#8216;Finance&#13;income / (costs) &amp;#8211; net.&amp;#8217;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Impairment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(i)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Trade and other receivables&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Trade and other receivables are assessed&#13;at each reporting date to determine whether there is objective evidence that they are impaired. Trade or other receivables are&#13;impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the receivable, and such&#13;loss event had a negative effect on the estimated future cash flows of that receivable that can be estimated reliably. Loss events&#13;include indications that a debtor is experiencing significant financial difficulty, default or delinquency in interest or principal&#13;payments, the probability that they will enter bankruptcy or other financial reorganization.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All receivables are assessed for specific&#13;impairment. Losses are recognized in profit or loss and reflected in an allowance account against receivables. When a subsequent&#13;event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. No&#13;impairments or reversals of impairments were recognized in 2015, 2016 or 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Intangible assets and leasehold improvements and equipment&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Assets that are subject to depreciation&#13;or amortization are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount may not be&#13;recoverable. An impairment loss is recognized as the amount by which an asset&amp;#8217;s carrying amount exceeds its recoverable amount.&#13;The recoverable amount is the higher of an asset&amp;#8217;s fair value less costs of disposal and value in use. Non- financial assets&#13;that were previously impaired are reviewed for possible reversal of the impairment at each reporting date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Income taxes comprise current and deferred&#13;tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly&#13;in equity or in other comprehensive loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Current tax is the expected tax payable&#13;or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date,&#13;and adjustments to taxes payable in respect of previous years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax is recognized in respect of&#13;temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used&#13;for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets and liabilities if the transaction&#13;which led to their initial recognition is a transaction that is not a business combination and that affects neither accounting&#13;nor taxable profit or loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax is measured at tax rates that&#13;are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively&#13;enacted by the reporting date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax assets and liabilities are&#13;presented net if there is a legally enforceable right to offset.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A deferred tax asset is recognized for&#13;unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits&#13;will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to&#13;the extent that it is no longer probable that the related tax benefit will be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Fair Value Measurement&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All assets and liabilities for which fair&#13;value is recognized in the consolidated financial statements are organized in accordance with the following fair value hierarchy,&#13;based on the lowest level input parameter that is significant on the whole for fair value measurement:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Level 1 &amp;#8211; Prices for identical assets or liabilities quoted in active markets (non-adjusted)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Level 2 &amp;#8211; Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Level 3 &amp;#8211; Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amount of all trade and other&#13;receivables, certificates of deposit, cash and cash equivalents and trade and other payables is a reasonable approximation of the&#13;fair value and therefore information about the fair values of those financial instruments has not been disclosed. The measurement&#13;of warrants and the convertible note designated at fair value through profit as well as the note disclosure for the fair value&#13;of a loan (financial liability) is based on level 2 measurement procedures (see notes 13 and 17).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Loss per share&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Loss per common share is calculated by&#13;dividing the loss of the period by the weighted average number of common shares outstanding during the period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has granted warrants under&#13;certain loan agreements (see note 17) and options under share-based payment programs (see note 16) which potentially have a dilutive&#13;effect; no instruments actually had a dilutive effect.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Critical judgments and accounting estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the consolidated financial&#13;statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application&#13;of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these&#13;estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Estimates and underlying assumptions are&#13;reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised&#13;and in any future periods affected.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In preparing these financial statements,&#13;the critical judgments made by management in applying the Company's accounting policies resulted in the following accounting estimates:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 47px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(i)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Share-based payments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0 0 0 28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of stock options issued&#13;by Affimed N.V. is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input&#13;parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends,&#13;the risk-free interest rate and the time to maturity of the option. The fair value of share-based equity-settled compensation plans&#13;is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity.&#13;The number of stock options expected to vest is estimated at each measurement date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 47px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Revenue recognition &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0 0 0 28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Elements of consideration in collaboration&#13;and license agreements are non-refundable up-front research funding payments, technology access fees and milestone payments. Generally,&#13;the Company has continuing performance obligations and therefore up-front payments are deferred and the related revenues recognized&#13;in the period of the expected performance. Technology access fees are generally deferred and recognized over the expected term&#13;of the research service agreement on a straight-line basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company estimates that the achievement&#13;of a milestone reflects a stage of completion under the terms of the agreements and recognizes revenue when a milestone is achieved.&#13;If the research service is cancelled due to technical failure, the remaining deferred revenues from upfront payments are recognized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 47px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(iii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Accrued expenses&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company estimates its accrued expenses&#13;reviewing quotations and contracts, identifying services that have been performed on its behalf, estimating the level of service&#13;performed and the associated cost incurred for the service when Affimed has not yet been invoiced or otherwise notified of the&#13;actual cost. The majority of Affimed&amp;#8217;s service providers invoice monthly in arrears for services performed or when contractual&#13;milestones are met. Affimed makes estimates of its accrued expenses as of each balance sheet date in the consolidated financial&#13;statements based on facts and circumstances known to it at that time. Affimed periodically confirms the accuracy of its estimates&#13;with the service providers and makes adjustments as necessary.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;New standards and interpretations applied&#13;for the first time&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;No new accounting standards adopted in&#13;2017 had a material impact on Affimed&amp;#8217;s consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;New standards and interpretations not&#13;yet adopted&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following new standards and amendments&#13;to standards are effective for annual periods beginning after December 31, 2017, and have not been applied in preparing these consolidated&#13;financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 45%; padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Standard / Amendment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 45%; padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Effective Date &lt;sup&gt;1&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;IFRS 15 Revenue from Contracts with Customers&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;IFRS 9 Financial Instruments (2014)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;IFRS 16 Leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Clarifications to IFRS 15 Revenue from Contracts with Customers&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Amendments&amp;#160;to&amp;#160;IFRS&amp;#160;2:&amp;#160;Classification&amp;#160;and&amp;#160;Measurement&amp;#160;of&amp;#160;Share-based&amp;#160;Payment&amp;#160;Transactions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Annual Improvements to IFRS Standards 2014-2016 Cycle (IFRS 1, IAS 28)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Amendments to IFRS 9: Prepayment Features with Negative Compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Amendments&amp;#160;to&amp;#160;IAS&amp;#160;28:&amp;#160;Long-term&amp;#160;Interests&amp;#160;in&amp;#160;Associates&amp;#160;and&amp;#160;Joint&amp;#160;Ventures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Annual Improvements to IFRS Standards 2015-2017 Cycle&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/120% Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;sup&gt;1&lt;/sup&gt; Shall apply for periods beginning&#13;on or after the effective date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company assessed the potential impact&#13;that IFRS 9, 15 or 16 will have on its consolidated financial statements. The other amended standards are not expected to have&#13;a significant effect on the consolidated financial statements of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;IFRS 9 (Financial Instruments)&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Classification&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The standard contains a new classification&#13;and measurement approach for financial instruments that reflects the business model in which assets are managed and their cash&#13;flow characteristics. Based on the new measurement requirements, Affimed will recognize its preferred shares in Amphivena at fair&#13;value and will increase retained earnings by approximately &amp;#8364;7 million before taxes as of January 1, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Hedge Accounting&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The new hedge accounting requirements will&#13;not have an impact on the consolidated financial statements as the Company does not have contracts or transactions which qualify&#13;for hedge accounting.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Impairment&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The new introduced impairment rules replace&#13;the &amp;#8216;incurred loss&amp;#8217; model in IAS 39 with a forward looking &amp;#8216;expected credit loss&amp;#8217; (&amp;#8220;ECL&amp;#8221;) model.&#13;This requires considerable judgement as to how changes in economic factors affect ECLs, which will be determined on a probability-weighted&#13;basis. Under IFRS 9, the Company has decided to measure loss allowances on the following basis:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; line-height: 107%"&gt;&lt;font style="font: 8pt/120% Arial, Helvetica, Sans-Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Cash and cash equivalents and financial assets: The Company determines the counterparties&amp;#8217; 12-month ECLs that result from possible default events within the 12 months after the reporting date based on the probability of default according to the Bloomberg database. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; line-height: 107%"&gt;&lt;font style="font: 8pt/120% Arial, Helvetica, Sans-Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Trade receivables: The Company determines the counterparties&amp;#8217; lifetime ECLs that result from all possible default events over the expected life of a financial instrument based on an estimated rating and corresponding probability of default rates according to the Bloomberg database. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Based on this methodology, incurred losses&#13;on cash and cash equivalents and on trade and other receivables as of December 31, 2017 would have no material impact on the consolidated&#13;financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;IFRS 15 (Revenue from contracts with customers)&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;IFRS 15 (Revenue from contracts with customers)&#13;establishes a comprehensive framework for determining whether, how much and when revenue is recognized. It replaces existing revenue&#13;recognition guidance, including IAS 18 Revenue, IAS 11 Construction Contracts and IFRIC 13 Customer Loyalty Programs. IFRS 15 has&#13;not been applied yet by Affimed but application will be required for periods beginning on or after January 1, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Affimed has finalized the assessment of&#13;all contracts with customers and IFRS 15 has no impact on the revenue recognition policy and revenue from current collaboration&#13;and service agreements which is recognized according to the stage of completion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;IFRS 16 (Leases)&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The new standard specifies how to recognize,&#13;measure, present and disclose lease agreements. The standard provides a single lessee accounting model, requiring lessees to recognize&#13;assets and liabilities for all leases unless the lease term is 12 months or less or the underlying asset has a low value. Affimed&#13;will be required to recognize &amp;#8220;right-of-use&amp;#8221; assets related to its premises rented and certain equipment leased. During&#13;the next year, the Company will gather and update information related to leases, assess extension and termination options as well&#13;as possible exemptions and identify the appropriate discount rate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0pt"&gt;&lt;/td&gt;&lt;td style="width: 35.45pt"&gt;&lt;font style="font-size: 8pt"&gt;(i)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Information about reportable segment&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is active in the discovery,&#13;pre-clinical and clinical development of antibodies based on its core technology. The activities are either conducted as own project&#13;development or for third party companies. Management of resources and reporting to the chief operating decision maker is based&#13;on the Company as a whole.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 35.45pt"&gt;&lt;font style="font-size: 8pt"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Geographic information&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The geographic information below analyzes&#13;the Company&amp;#8217;s revenue and non-current assets by country. In presenting the following information, segment revenue has been&#13;based on the geographic location of the customers and segment assets were based on the geographic location of the assets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Discovery activities and research services&#13;are conducted in both the Heidelberg and Plzen premises. Pre-clinical and clinical activities are conducted and coordinated from&#13;Heidelberg.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: bold 8pt Times New Roman, Times, Serif"&gt;Revenues:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Germany&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;125&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;80&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Europe&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;711&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,397&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,236&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 3.5pt"&gt;USA&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;6,725&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;4,911&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;694&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;7,562&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;6,314&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;2,010&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Non-current assets as of December 31:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Germany&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;618&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;957&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Czech Republic&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;259&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;221&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;877&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,178&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0pt"&gt;&lt;/td&gt;&lt;td style="width: 35.45pt"&gt;&lt;font style="font-size: 8pt"&gt;(iii)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Major Customers&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the years ended December 31, 2015,&#13;2016 and 2017, the Company&amp;#8217;s revenue with two, three and four customers, respectively, exceeded 10% of total revenues.&lt;/p&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Collaboration agreement with Amphivena&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Until July 2016, Affimed was party&#13;to a collaboration with Amphivena. The purpose of the collaboration was the development of a product candidate for hematological&#13;malignancies. The collaboration included a License and Development Agreement between Amphivena and Affimed, which expired when&#13;Amphivena obtained the approval of an investigational new drug application (IND) from the FDA in July 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;Pursuant to the license and development&#13;agreement between Affimed and Amphivena, Affimed granted a license to intellectual property and agreed to perform certain services&#13;for Amphivena related to the development of a product candidate for hematological malignancies. In consideration for the research&#13;and development work that was performed, Amphivena was required to pay to Affimed service fees totaling approximately &amp;#8364;16&#13;million payable according to the achievement of milestones and phase progressions as described under the license and development&#13;agreement. Since the expiration of the agreement, the parties have been closing out the collaboration by exchanging documentation&#13;and transferring materials and third-party contracts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;During the years ended December&#13;31, 2015, 2016 and 2017, the Company recognized revenue upon achievement of milestones and for the performance of research and&#13;development services (net of Affimed&amp;#8217;s share in funding Amphivena) totaling &amp;#8364;4.8 million, &amp;#8364;3.4 million and &amp;#8364;0.2&#13;million, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amphivena has obtained funding solely by&#13;issuing preferred stock and convertible notes to investors. Through December 31, 2017, Affimed participated in the financing of&#13;Amphivena with cash investments in stock of &amp;#8364;2.3 million and in convertible notes of &amp;#8364;0.3 million ( see note 13).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Collaboration agreement with The Leukemia&#13;&amp;#38; Lymphoma Society (LLS)&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Affimed is party to a collaboration with&#13;LLS to fund the development of a specific product candidate (TandAb). Under the terms of the agreement, LLS has agreed to contribute&#13;up to $4.4 million contingent upon the achievement of certain milestones.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the event that the research and development&#13;is successful, Affimed must proceed with commercialization of the licensed product. If Affimed decides for business reasons not&#13;to continue the commercialization, Affimed must at its option either repay the amount funded or grant a license to LLS to enable&#13;LLS to continue with the development program. In addition, LLS is entitled to receive royalties from Affimed based on the Company&amp;#8217;s&#13;future revenue from any licensed product, with the amount of royalties not to exceed three times the amount funded.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2016, the research funding agreement&#13;with LLS was amended to reflect a shift to the development of combination therapeutic approaches so that the milestones now relate&#13;primarily to the development of a combination therapy.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ended December 31, 2015,&#13;2016 and 2017, the Company achieved several milestones and recognized revenue totaling &amp;#8364;1.6 million, &amp;#8364;0.4 million and&#13;&amp;#8364;0.2 million, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Research service agreements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;AbCheck has entered into certain research&#13;service agreements. These research service agreements provide for non-refundable upfront technology access research funding or&#13;capacity reservation fees and milestone payments. The Company recognized revenue of &amp;#8364;1.1 million, &amp;#8364;2.4 million and&#13;&amp;#8364;1.6 million during the years ended December 31, 2015, 2016 and 2017, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other income and expenses, net mainly comprises&#13;income from government grants for research and development projects of &amp;#8364;195 (2016: &amp;#8364;171, 2015: &amp;#8364;716).&lt;/p&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory>
    <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the different&#13;types of expenses allocated to research and development costs for the years ended December 31:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Third-party services&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;15,386&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;20,170&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;12,299&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Personnel expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;3,637&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;6,648&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;5,639&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Legal, consulting and patent expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;902&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;758&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;890&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Cost of Materials&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;902&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,028&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;994&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Amortization and depreciation&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;308&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;322&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;309&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Operating lease expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;267&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;297&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;345&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;606&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;957&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;22,008&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;30,180&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;21,489&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the different&#13;types of expenses allocated to general and administrative costs for the years ended December 31:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Personnel expenses&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;3,658&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;4,729&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;4,521&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Legal, consulting and audit fees&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;2,468&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;2,210&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,945&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Operating lease expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;89&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;111&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;126&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,333&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,273&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,394&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;7,548&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;8,323&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;7,986&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the items of&#13;employee benefits for the years ended December 31:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Wages and salaries&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;5,066&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;7,445&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;7,475&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Social security costs&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;583&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;807&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;931&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;5,649&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;8,252&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;8,406&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the items of&#13;finance income and costs for the years ended December 31:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2015&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; text-align: left; padding-left: 3.5pt"&gt;Interest Perceptive Loan Agreement (see note 17)&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(703&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(762&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Other finance cost Perceptive Loan Agreement (see note 17)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(242&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Interest SVB Loan Agreement (see note 17)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(41&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(690&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Foreign exchange differences&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,808&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;691&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,378&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Interest on certificates of deposit with maturities of more than three months (see note 14)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Other finance income/finance costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Finance income/costs - net&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,104&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(230&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,983&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company did not incur any material&#13;income tax in the periods presented. As of December 31, 2017 deferred tax liabilities from temporary differences result mainly&#13;from borrowings (&amp;#8364;152; 2016: &amp;#8364;129) and in 2016 from other assets (&amp;#8364;121). Deferred tax assets from differences&#13;mainly resulting from trade and other receivables (&amp;#8364;259; 2016: &amp;#8364;292) and intangible assets (&amp;#8364;405; 2016: &amp;#8364;49)&#13;have not been recognized as deferred tax assets as no sufficient future taxable profits or offsetting deferred tax liabilities&#13;are available.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation between actual income&#13;taxes and the expected tax benefit from the loss before tax multiplied by the Company's applicable tax rate is presented below&#13;for the years ended December 31:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Loss before tax&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(20,239&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(32,274&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(30,243&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Income tax benefit at tax rate of 29.825 %&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;6,036&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;9,626&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;9,020&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Adjustments due to impairment of deferred tax assets&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(6,251&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(8,747&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(9,036&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Permanent differences&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;199&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(948&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(93&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Adjustments for local tax rates&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;18&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;195&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Non deductible expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;163&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;154&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;16&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Other&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(165&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(82&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Income taxes&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;58&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;20&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In Germany, Affimed has tax losses carried&#13;forward of &amp;#8364;146.8 million (2016: &amp;#8364;117.4 million) for corporate income tax purposes and of &amp;#8364;146.4 million (2016:&#13;&amp;#8364;117.0 million) for trade tax purposes that are available indefinitely for offsetting against future taxable profits of that&#13;entity. Restrictions on the utilization of tax losses in case of a change of control of ownership in Affimed were mitigated by&#13;the enactment of the Economic Growth Acceleration Act (Wachstumsbeschleunigungsgesetz 2009). According to the provisions of this&#13;act unused tax losses of a corporation as at the date of a qualified change in ownership are preserved to the extent they are compensated&#13;by an excess of the fair value of equity for tax purposes above its carrying amount of the Company. The maximum amount of tax losses&#13;at risk of being lost due to ownership changes is approximately &amp;#8364;59 million. Deferred tax assets have not been recognized&#13;in respect of any losses carried forward as no sufficient taxable profits of Affimed are expected.&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The trade receivables as of December 31,&#13;2017 and 2016, of &amp;#8364;580 and &amp;#8364;970, respectively, are all due in the short-term, do not bear interest and are not impaired.&#13;As of December 31, 2017 and 2016, &amp;#8364;260 and &amp;#8364;219, respectively were overdue. Other receivables are all due short-term&#13;and mainly comprise receivables for research and development grants and other government subsidies of &amp;#8364;20 (2016: &amp;#8364;14),&#13;value-added tax receivables of &amp;#8364;186 (2016: &amp;#8364;642) and in 2016 receivables related to refunding of research and development&#13;costs (&amp;#8364;385).&lt;/p&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On December&#13;27, 2017, the Company signed a note purchase agreement with Amphivena pursuant to which Amphivena issued the Company a convertible&#13;note with a principal amount of USD 0.35 million (&amp;#8364;0.29 million) and warrants to purchase 46,667 common shares of Amphivena&#13;with an exercise price of USD 0.01 per common share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The loan matures on December 27, 2018&#13;and bears interest at a rate of 6% per annum payable at maturity. The convertible note allows for a conversion into common shares&#13;of Amphivena during the term of the note at a conversion price which is contingent on various conversion triggers. If no conversion&#13;occurs prior to the maturity date the note will be converted into shares of Amphivena at a conversion price of USD 1.5 per common&#13;share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The contractual life of the warrants&#13;is five years or until the date of certain transactions, e.g. the transfer of the majority of the voting rights in Amphivena, the&#13;transfer of substantially all of the assets of Amphivena, or an initial public offering covering the offering and sale of Amphivena&amp;#8217;s&#13;common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognized the note and&#13;the warrants in the consolidated financial statements as of December 31, 2017 at their respective fair values.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As of December&#13;31, 2016, financial assets consisted of U.S. Dollar denominated certificates of deposit with original maturities of more than three&#13;months.&lt;/p&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2017, the share capital&#13;of &amp;#8364;468 (2016: &amp;#8364;333) is composed of 46,791,352 (2016: 33,262,745) common shares with a par value of &amp;#8364;0.01.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the first quarter of 2017, the&#13;Company issued 10,646,762 common shares in a public offering at a price of $1.80 per common share for net proceeds of&#13;approximately &amp;#8364;16 million. In connection with its at-the-market sales agreement, the Company issued 2,881,845 common&#13;shares for net proceeds of &amp;#8364;5.1 million in 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 20, 2017, the authorized share&#13;capital was increased from &amp;#8364;1,100 to &amp;#8364;2,196, consisting of 109,800,000 common shares and 109,800,000 cumulative preference&#13;shares, each with a par value of &amp;#8364;0.01 per share. As of December 31, 2017, 46,791,352 (December 31, 2016: 33,262,745) common&#13;shares have been issued and are outstanding. Preferred shareholders are entitled to receive a fixed dividend per year in arrears&#13;prior to any distributions to common shareholders. As of December 31, 2017, no preferred shares have been issued.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2014, an equity-settled share-based&#13;payment program was established by Affimed N.V. (ESOP 2014).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under this program, the Company granted&#13;awards to certain members of the Management Board, the Supervisory Board, non-employee consultants and employees. The awards vest&#13;in installments over three years and can be exercised up to 10 years after the grant date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Share based payments with employees&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company granted 1,778,095 ESOP 2014&#13;awards in 2016 and 1,436,075 awards in 2017 to employees, members of the Management Board and others providing similar services&#13;(certain consultants).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/120% Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2017, 399,552 ESOP 2014 awards were&#13;cancelled or forfeited due to termination of employment (2016: 83,750), and no options were exercised. As of December 31, 2017,&#13;4,080,868 ESOP 2014 awards were outstanding (December 31, 2016: 3,044,345), 2,001,264 awards (December 31, 2016: 952,458) were&#13;vested. The options outstanding as of December 31, 2017 had an exercise price in the range of $1.80 to $13.47 (2016: $2.51 to $13.47)&#13;and weighted average remaining contractual life of 8.4 years (2016: 8.9 years).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;In&#13;2017, an expense of &amp;#8364;1.943 was recognized affecting research and development expenses (&amp;#8364;522) and general and administrative&#13;expenses (&amp;#8364;1,421). In 2016, an expense of &amp;#8364;3,545 was recognized affecting&lt;/font&gt; research and development expenses&#13;(&amp;#8364;1,178) and general and administrative expenses (&amp;#8364;2,367). In 2015, an expense of &amp;#8364;2,220 was recognized affecting&#13;research and development expenses (&amp;#8364;611) and general and administrative expenses (&amp;#8364;1,609).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of options was determined&#13;using the Black-Scholes valuation model. The significant inputs into the valuation model are as follows (weighted average):&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 3.5pt"&gt;Fair value at grant date&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;Share price at grant date&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;Exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Expected life&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.32&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.23&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Expected volatility is estimated based&#13;on the observed daily share price returns of a peer group measured over a historic period equal to the expected life of the awards.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Share based payments with non-employees&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 27, 2017, Affimed entered into&#13;a consulting agreement for business development services with a non-employee consultant. Pursuant to the agreement the consultant&#13;received an initial award of 60,000 options to purchase common shares of Affimed N.V. with an exercise price of USD 1.25. These&#13;options only vest with the achievement of a future event as defined in the consulting agreement. Affimed recognizes the expense&#13;related to the awards on the conclusion of such an event which was not concluded as of December 31, 2017.&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:DisclosureOfBorrowingsExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Perceptive&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2014, the Company entered into&#13;a loan agreement with an affiliate of Perceptive Advisors LLC (the &amp;#8220;Perceptive loan&amp;#8221;), drawing an amount of $5.5 million.&#13;Finance costs included interest, an arrangement fee and 106,250 warrants convertible into common shares of the Company with a strike&#13;price of $8.80. Upon initial recognition, the fair value of the warrant of &amp;#8364;613 was recognized in equity, net of tax of &amp;#8364;183.&#13;Fair value was determined using the Black-Scholes-Merton formula, with an expected volatility of 65% and an expected time of six&#13;years to exercise of the warrant. The contractual maturity of the warrant is ten years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2016 the Company repaid all outstanding&#13;amounts under the Perceptive loan. The Company recognized early repayment fees of &amp;#8364;110 and extinguishment losses of &amp;#8364;132.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The loan was measured at amortized cost&#13;using the effective interest method. In 2016, interest costs of &amp;#8364;762 (2015: &amp;#8364;703) and foreign exchange losses of &amp;#8364;86&#13;(2015: &amp;#8364;527) were recognized in profit or loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Silicon Valley Bank&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 30, 2016, the Company entered&#13;into a loan agreement with Silicon Valley Bank (the &amp;#8220;SVB loan&amp;#8221;) which provides the Company with a senior secured term&#13;loan facility for up to &amp;#8364;10.0 million, which agreement was amended in May 2017 to provide that such amount would be available&#13;in three tranches. In December 2016, the Company drew an initial tranche of &amp;#8364;5.0 million and in May 2017, a second tranche&#13;of &amp;#8364;2.5 million; the availability of a third tranche of &amp;#8364;2.5 million expired in September 2017 with such amount remaining&#13;undrawn.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Finance costs comprise the interest rate&#13;of one-month EURIBOR plus an applicable margin of 5.5%, with a floor of 5.5%, related one-time legal and arrangement fees of &amp;#8364;236&#13;and a final payment fee equal to 10% of the total principal amount to be paid with the last instalment. Pursuant to the loan agreement,&#13;the Company also granted the lender 166,297 and 53,395 warrants with an exercise price of $2.00 and $2.30 per share, respectively.&#13;Each warrant can be used to purchase common shares of Affimed at the respective exercise price for a period of ten years from the&#13;date of grant. The fair value of the warrants of &amp;#8364;192 less deferred taxes and transaction costs of &amp;#8364;81 and &amp;#8364;8,&#13;respectively, was recorded as an addition to capital reserves in the equity of Affimed. The fair value of the warrants was determined&#13;using the Black-Scholes-Merton valuation model, with an expected volatility of 75-80% and an expected exercise period of five years&#13;to exercise of the warrant. The contractual maturity of the warrants is ten years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2017, the Company adjusted the carrying&#13;amount of its financial liability and recorded a gain of &amp;#8364;0.2 million upon the drawing of the second tranche due to a change&#13;in timing of the cash flows under the original terms of the existing credit facility.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The loan is secured by a pledge of 100%&#13;of Company&amp;#8217;s ownership interest in Affimed GmbH, all intercompany claims owed to Affimed N.V. by its subsidiaries, and collateral&#13;agreements for all bank accounts, inventory, trade receivables and other receivables of Affimed N.V. and Affimed GmbH recognized&#13;in the consolidated financial statements with the following book values:&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center"&gt;Book value as of December 31, 2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center"&gt;Book value as of December 31, 2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt; padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Consolidated financial statements&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;thereof assets pledged&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Consolidated financial statements&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;thereof assets pledged&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 11pt; padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 3.5pt"&gt;Leasehold improvements and equipment&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;822&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;542&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;891&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;Inventories&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;219&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Trade and other receivables&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,102&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;328&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Other assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;516&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;292&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Financial assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;35,407&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;34,674&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;39,837&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38,726&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-size: 11pt; padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,684&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,096&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,093&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2017 and 2016, the fair&#13;value of the liability did not differ significantly from its carrying amount (&amp;#8364;7,169 and &amp;#8364;4,590). The loan has a maturity&#13;date of May 31, 2020, and repayment started in December 2017 with amortized payments of principal in equal monthly installments.&#13;As of December 31, 2017, &amp;#8364;3,083 (2016: &amp;#8364;973) of such amount was classified as current liabilities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DisclosureOfBorrowingsExplanatory>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Trade and other payables comprise trade&#13;payables of &amp;#8364;3,380 (2016: &amp;#8364;4,506). Other payables mainly comprise payroll and employee related liabilities for withholding&#13;taxes and social security contributions of &amp;#8364;514 (2016: &amp;#8364;471) and payables due to employees for outstanding bonus, unused&#13;holidays and other accruals. Other payables are normally settled within 30 days.&lt;/p&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Loss per common share is calculated by&#13;dividing the loss of the period by the weighted average number of common shares outstanding during the period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(20,239&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(32,216&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(30,223&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Weighted number of common shares outstanding&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;28,477,438&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;33,259,505&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;43,746,073&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Loss per share in &amp;#8364; per share&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(0.71&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(0.97&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(0.69&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;No instruments had a dilutive effect.&lt;/p&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 21.3pt"&gt;&lt;font style="font-size: 8pt"&gt;(i)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Lease and other commitments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has entered into rental agreements&#13;for premises as well as into leases for vehicles and the use of licenses. These agreements have an average non-cancellable term&#13;of between one and four years with renewal options included in some contracts. In 2017, lease expenses of &amp;#8364;472 and license&#13;fees of &amp;#8364;174 have been recognized in consolidated statement of comprehensive income (2016: &amp;#8364;409 and &amp;#8364;405; 2015:&#13;&amp;#8364;356 and &amp;#8364;278).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Future minimum lease payment obligations&#13;under non-cancellable operating leases as of the reporting date are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 3.5pt"&gt;Within one year&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;470&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Between one and five years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;541&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;363&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-size: 11pt; padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,241&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;833&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 28.35pt"&gt;&lt;font style="font-size: 8pt"&gt;(i)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Contingencies&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Affimed has entered into various license&#13;agreements that contingently trigger payments upon achievement of certain milestones and royalty payments upon commercialization&#13;of a product in the future.&lt;/p&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.05pt"&gt;&lt;/td&gt;&lt;td style="width: 14.15pt"&gt;&lt;font style="font-size: 8pt"&gt;(i)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Shareholders&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2017, no shareholder&#13;(December 31, 2016: one shareholder) holds more than 20% of the voting rights.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0.05pt"&gt;&lt;/td&gt;&lt;td style="width: 14.15pt"&gt;&lt;font style="font-size: 8pt"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Transactions with key management personnel&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The compensation of managing directors&#13;and other key management personnel comprised of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Short-term employee benefits&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,633&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,879&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,538&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Termination benefits&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;430&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Share-based payments&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,474&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;2,292&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,379&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;3,107&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;4,601&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;2,917&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Remuneration of Affimed&amp;#8217;s managing&#13;directors comprises fixed and variable components and share-based payment awards. In addition, the managing directors receive supplementary&#13;benefits such as fringe benefits and allowances. In the case of an early termination, the managing directors receive  severance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Compensation for other key management personnel&#13;comprises fixed and variable components and share-based payment awards.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The supervisory directors of Affimed N.V.&#13;received compensation for their services on the supervisory board of &amp;#8364;375 (2016: &amp;#8364;350; 2015: &amp;#8364;296). In 2017,&#13;the Company recognized expenses for share-based payments for supervisory board members of &amp;#8364;144 (2016: &amp;#8364;381, 2015: &amp;#8364;478).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Selected managing directors and supervisory&#13;directors entered into service and consulting agreements with the Company:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Dr. Ulrich Grau is a significant shareholder&#13;and Chairman of the Board of Directors of i-novion Inc., which was engaged by the Company to conduct preclinical services. In 2016,&#13;i-novion Inc. received related payments of &amp;#8364;86.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Jens-Peter Marschner rendered consulting&#13;services amounting to &amp;#8364;11 in 2017 and &amp;#8364;29 in 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table provides the total&#13;amounts of outstanding balances related to key management personnel:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5" style="font: 8pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding balances&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December 31, 2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 56%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Thomas Hecht&lt;/td&gt;&lt;td style="width: 8%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;23&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Richard Stead&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Berndt Modig&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;8&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Ferdinand Verdonck&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;10&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;10&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Ulrich Grau&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;17&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;17&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Bernhard Ehmer&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;10&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Jens-Peter Marschner&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;2&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory contextRef="From2017-01-01to2017-12-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(i)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Financial risk management objectives and policies&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s principal financial&#13;instruments comprise cash and cash equivalents, certificates of deposit at commercial banks, a convertible loan, warrants and investor&#13;loans presented in borrowings. The main purpose of these financial instruments is to raise funds for the Company's operations.&#13;The Company has various other financial assets and liabilities such as trade and other receivables and trade and other payables,&#13;which arise directly from its operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The main risks arising from the Company's&#13;financial instruments are credit risk and liquidity risk. The measures taken by management to manage each of these risks are summarized&#13;below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Credit risk&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s financial assets comprise&#13;to a large extent cash and cash equivalents. In addition, financial assets include certificates of deposit, a convertible loan,&#13;warrants and trade and other receivables. The total carrying amount of cash and cash equivalents (&amp;#8364;39.8 million, 2016: &amp;#8364;35.4&#13;million), trade and other receivables (&amp;#8364;1.1 million, 2016: &amp;#8364;2.3 million), convertible note and warrants of Amphivena&#13;(&amp;#8364;0.3 million) and in 2016, certificates of deposit (&amp;#8364;9.5 million) represents the maximum credit exposure of &amp;#8364;41.2&#13;million (2016: &amp;#8364;47.2 million).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The cash and cash equivalents and certificates&#13;of deposit are held with banks, which are rated BBB+ to AA- based on Standard &amp;#38; Poor&amp;#8217;s and Moody&amp;#8217;s.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(iii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Interest rate risk&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s interest rate risk&#13;arises from cash accounts and long-term borrowings at variable rates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Affimed entered into the SVB loan pursuant&#13;to which the Company borrowed &amp;#8364;7.5 million with a variable interest rate of an annual rate of 5.5% plus one-month EURIBOR,&#13;with EURIBOR deemed to equal zero percent if EURIBOR is less than zero percent. The Company does not expect the EURIBOR to exceed&#13;the floor of 0% within the foreseeable future, and considers the interest risk to be low.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/120% Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Market interest rates on cash and cash&#13;equivalents as well as on term deposits were low in 2017, resulting in interest income of &amp;#8364;93 in 2017. A shift in interest&#13;rates (increase or decrease) would not have a material impact on the loss of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(iv)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Other price risks&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company holds warrants and a convertible&#13;loan of Amphivena. The fair value of the convertible loan and the warrants depends on the share price. The total exposure of the&#13;Company amounts to &amp;#8364;292.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(v)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Foreign currency risk&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Foreign exchange risk arises when future&#13;commercial transactions or recognized assets or liabilities are denominated in a currency that is not the entity&amp;#8217;s functional&#13;currency.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s entities are exposed&#13;to Czech Koruna (CZK) and US Dollars (USD). The net exposure as of December 31, 2017 was &amp;#8364;18,768 (2016: &amp;#8364;18,974) and&#13;mainly relates to US Dollars.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2017, if the Euro had weakened/strengthened&#13;by 10% against the US dollar with all other variables held constant, the loss would have been &amp;#8364;1,877 (2016: &amp;#8364;1,897)&#13;higher/lower, mainly as a result of foreign exchange gains/losses on translation of US dollar-denominated financial assets. The&#13;Company considers a shift in the exchange rates of 10% as a realistic scenario.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Loss is less sensitive to movement in exchange&#13;rates shifts in 2017 than in 2016 because of the decreased volume of US dollar-denominated transactions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following significant exchange rates&#13;have been applied during the year:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 3.5pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;CZK or USD/EUR&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;CZK or USD/EUR&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;CZK or USD/EUR&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 3.5pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 46%; padding-left: 3.5pt; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;CZK - Average Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.03666&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.03699&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.03799&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 3.5pt; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;CZK - Spot rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.03701&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.03701&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.03916&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 3.5pt; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 3.5pt; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;USD - Average Rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.90190&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.90404&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.88519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 3.5pt; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;USD - Spot rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.91853&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.94868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.83382&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; line-height: 107%"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(vi)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Liquidity risk&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Liquidity risk is the risk that the Company&#13;will encounter difficulties in meeting the obligations associated with its financial liabilities which are normally settled by&#13;delivering cash. The Company&amp;#8217;s approach to managing liquidity is to ensure, as far as possible, that it will always have&#13;sufficient liquidity to meet its liabilities when due.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company continually monitors its risk&#13;of a shortage of funds using short and mid-term liquidity planning. This takes account of the expected cash flows from all activities.&#13;The supervisory board undertakes regular reviews of the budget.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2016, 2017 and February 2018, Affimed&#13;raised significant funding that it estimates will enable the Company to fund operating expenses and capital expenditure requirements&#13;at least until the fourth quarter of 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has entered into an at-the-market&#13;sales agreement with Cowen &amp;#38; Company, LLC under which more than &amp;#8364;5 million in net proceeds has been raised (see note&#13;15).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the first quarter of 2017, the Company&#13;issued 10,646,762 common shares in a public offering at a price of $1.80 per common share for net proceeds of approximately &amp;#8364;16&#13;million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 30, 2016, the Company entered&#13;into a loan agreement with Silicon Valley Bank (the &amp;#8220;SVB loan&amp;#8221;) and drew the initial tranche of &amp;#8364;5.0 million&#13;in December 2016 and a second tranche of &amp;#8364;2.5 million in May 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2018, the Company issued 13,225,000&#13;common shares in a public offering at a price of $2.00 per common share for net proceeds of approximately &amp;#8364;19.7 million.&#13;In addition, in February 2018 the Company issued 2,373,716 common shares for net proceeds of approximately &amp;#8364;3.8 million in&#13;connection with its at-the-market sales agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expects to require additional&#13;funding to complete the development of the existing product candidates. In addition, the Company expects to require additional&#13;capital to commercialize the products if regulatory approval is received.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 0px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 38px; line-height: 107%"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;(vii)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Capital management&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The primary objective of the Company's&#13;capital management is to ensure that it maintains its liquidity in order to finance its operating activities and meet its liabilities&#13;when due.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0"&gt;The Company manages its capital structure primarily through&#13;equity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2018, the Company issued 13,225,000&#13;common shares in a public offering at a price of $2.00 per common share for net proceeds of approximately &amp;#8364;19.7 million.&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company provides research and development&#13;services to third parties based on both Company and third party owned intellectual property. Such services are performed on a &amp;#8220;best&#13;efforts&amp;#8221; basis without a guarantee of technological or commercial success. For some research programs, Affimed has entered&#13;into collaborations with other companies that provide the Company with funding or other resources such as access to technologies.&#13;From time to time, the Company also licenses its intellectual property to third parties who use it to develop product candidates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Collaboration and license agreements are&#13;evaluated to determine whether they involve multiple elements that can be considered separate units of accounting. To date, the&#13;Company has not licensed or sold its intellectual property without continuing involvement by providing the related research and&#13;development services. Accordingly, the results under the Company&amp;#8217;s collaboration and license agreements have not qualified&#13;as separate units of accounting.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue from collaborative or other research&#13;service agreements is recognized according to the stage of completion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Milestone payments are contingent upon&#13;the achievement of contractually stipulated targets. The achievement of these targets or milestones depends largely on meeting&#13;specific requirements laid out in the respective agreement. Consideration that is contingent upon achievement of a milestone is&#13;recognized in its entirety as revenue in the period in which the milestone is achieved, but only if the consideration earned from&#13;the achievement of a milestone meets all the criteria for the milestone to be considered substantive at the inception of the agreement.&#13;For a milestone to be considered substantive, the consideration earned by achieving the milestone must (i) be commensurate with&#13;the Company&amp;#8217;s performance to achieve the milestone, (ii) relate solely to past performance, and (iii) be reasonable relative&#13;to all results and payment terms subject to the respective agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Non-refundable upfront research funding&#13;that generally has no stand-alone value to the customer and requires continuing involvement in the form of research and development&#13;services or other efforts by the Company is recognized as revenue ratably over the term of the service agreement which is the period&#13;of performance.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Costs incurred related to research activities&#13;are expensed in the period incurred. Costs incurred on development projects are recognized as intangible assets beginning on the&#13;date it can be established that it is probable that future economic benefits attributable to the asset will flow to the Company&#13;considering its technological and commercial feasibility. Given the current stage of the development of the Company&amp;#8217;s product&#13;candidates and technologies, no development expenditures have yet been capitalized. Intellectual property-related costs for patents&#13;are part of the expenditure for the research and development projects. Therefore, registration costs for patents are expensed when&#13;incurred as long as the research and development project concerned does not meet the criteria for capitalization.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 28.35pt"&gt;&lt;font style="font-size: 8pt"&gt;(i)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Short-term employee benefits&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Short-term employee benefit obligations&#13;are measured on an undiscounted basis and are expensed as the related service is provided.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A liability is recognized for the amount&#13;expected to be paid under a short-term cash bonus, if (a) the Company has a present legal or constructive obligation to pay this&#13;amount as a result of past service provided by the employee, and (b) the obligation can be estimated reliably.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 28.35pt"&gt;&lt;font style="font-size: 8pt"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Share-based payment transactions&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s share-based payment&#13;awards outstanding as of December 31, 2016 and 2017, are classified as equity-settled share-based plans. The fair value of share-based&#13;equity-settled awards granted to employees is measured at grant date and compensation cost is recognized over the vesting period&#13;with a corresponding increase in equity. Share-based payment awards with non-employees are measured and recognized when services&#13;are received. Fair value is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based&#13;on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns,&#13;dividends, the risk-free interest rate and the time to maturity of the option. The number of stock options expected to vest is&#13;estimated at each measurement date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company receives certain government&#13;grants that support its research effort in specific projects. These grants generally provide for reimbursement of approved costs&#13;incurred as defined in the respective grants. Income in respect of grants also includes contributions towards the costs of research&#13;and development. Income is recognized when costs under each grant are incurred in accordance with the terms and conditions of the&#13;grant and the collectability of the receivable is reasonably assured.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Government grants relating to costs are&#13;deferred and recognized in the income statement over the period necessary to match them with the costs they are intended to compensate.&#13;When the cash in relation to recognized government grants is not yet received the amount is included as a receivable on the statement&#13;of financial position.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes income from government&#13;grants under &amp;#8216;Other income - net&amp;#8217; in the consolidated statement of comprehensive loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Payments made under operating leases are&#13;recognized in profit or loss on a straight-line basis over the term of the lease.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Finance income comprises interest income&#13;from interest bearing bank deposits. Interest income is recognized as it accrues using the effective interest method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Finance costs comprise interest expense&#13;on borrowings and, in 2016, includes losses from early extinguishment of debt.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A financial instrument is any contract&#13;that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 28.35pt"&gt;&lt;font style="font-size: 8pt"&gt;(i)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Non-derivative financial assets&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s non-derivative financial&#13;assets include trade and other receivables, cash and cash equivalents and, in 2016, certificates of deposit at banks with original&#13;maturities of more than three months.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Loans and receivables are non-derivative&#13;financial assets with fixed or determinable payments that are not quoted in an active market. They are included in current assets&#13;and are subsequently carried at amortized cost using the effective interest method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents comprise cash&#13;balances and call deposits with original maturities of three months or less.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 28.35pt"&gt;&lt;font style="font-size: 8pt"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Non-derivative financial liabilities&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-indent: 0in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#8217;s classes of financial&#13;liabilities are borrowings and trade and other payables. The Company initially recognizes non-derivative financial liabilities&#13;on the date that they are originated and measures them at amortized cost using the effective interest rate method. The Company&#13;derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 28.35pt"&gt;&lt;font style="font-size: 8pt"&gt;(iii)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Compound financial instruments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company entered into certain loan agreements&#13;pursuant to which it issued warrants to purchase common shares of the Company at the option of the respective holders (see note&#13;17). The number of shares to be issued does not vary with changes in their fair value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The liability component of the loans was&#13;recognized initially at the fair value of a similar liability without a warrant. The equity component was recognized initially&#13;at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component.&#13;Subsequent to initial recognition, the liability component is measured at amortized cost using the effective interest method. The&#13;equity component is not re-measured subsequent to initial recognition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2017, the Company entered into a convertible&#13;note agreement (see note 13). The Company designated the combined contract consisting of the loan component and the conversion&#13;feature embedded in the loan agreement at fair value through profit and loss and recognizes changes of fair value re-measured on&#13;a recurring basis in &amp;#8216;Finance income / (costs) &amp;#8211; net.&amp;#8217;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 28.35pt"&gt;&lt;font style="font-size: 8pt"&gt;(i)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Derivatives&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company acquired warrants to purchase&#13;common shares of Amphivena Therapeutics Inc. (&amp;#8220;Amphivena&amp;#8221;) at a specified price (see note 13). Initially, the warrants&#13;were recognized at fair value. Subsequently the fair value is re-measured on a recurring basis with changes recognized in &amp;#8216;Finance&#13;income / (costs) &amp;#8211; net.&amp;#8217;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 28.35pt"&gt;&lt;font style="font-size: 8pt"&gt;(i)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Trade and other receivables&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Trade and other receivables are assessed&#13;at each reporting date to determine whether there is objective evidence that they are impaired. Trade or other receivables are&#13;impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the receivable, and such&#13;loss event had a negative effect on the estimated future cash flows of that receivable that can be estimated reliably. Loss events&#13;include indications that a debtor is experiencing significant financial difficulty, default or delinquency in interest or principal&#13;payments, the probability that they will enter bankruptcy or other financial reorganization.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All receivables are assessed for specific&#13;impairment. Losses are recognized in profit or loss and reflected in an allowance account against receivables. When a subsequent&#13;event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. No&#13;impairments or reversals of impairments were recognized in 2015, 2016 or 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 28.35pt"&gt;&lt;font style="font-size: 8pt"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 8pt"&gt;Intangible assets and leasehold improvements and equipment&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Assets that are subject to depreciation&#13;or amortization are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount may not be&#13;recoverable. An impairment loss is recognized as the amount by which an asset&amp;#8217;s carrying amount exceeds its recoverable amount.&#13;The recoverable amount is the higher of an asset&amp;#8217;s fair value less costs of disposal and value in use. Non- financial assets&#13;that were previously impaired are reviewed for possible reversal of the impairment at each reporting date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Income taxes comprise current and deferred&#13;tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly&#13;in equity or in other comprehensive loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Current tax is the expected tax payable&#13;or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date,&#13;and adjustments to taxes payable in respect of previous years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax is recognized in respect of&#13;temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used&#13;for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets and liabilities if the transaction&#13;which led to their initial recognition is a transaction that is not a business combination and that affects neither accounting&#13;nor taxable profit or loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax is measured at tax rates that&#13;are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively&#13;enacted by the reporting date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax assets and liabilities are&#13;presented net if there is a legally enforceable right to offset.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A deferred tax asset is recognized for&#13;unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits&#13;will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to&#13;the extent that it is no longer probable that the related tax benefit will be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All assets and liabilities for which fair&#13;value is recognized in the consolidated financial statements are organized in accordance with the following fair value hierarchy,&#13;based on the lowest level input parameter that is significant on the whole for fair value measurement:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 28.35pt"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 1 &amp;#8211; Prices&#13;for identical assets or liabilities quoted in active markets (non-adjusted)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 28.35pt"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 2 &amp;#8211; Measurement&#13;procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly&#13;observable for on the market&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 28.35pt"&gt;&lt;font style="font: 8pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Level 3 &amp;#8211; Measurement&#13;procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly&#13;observable for on the market&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The carrying amount of all trade and other&#13;receivables, certificates of deposit, cash and cash equivalents and trade and other payables is a reasonable approximation of the&#13;fair value and therefore information about the fair values of those financial instruments has not been disclosed. The measurement&#13;of warrants and the convertible note designated at fair value through profit as well as the note disclosure for the fair value&#13;of a loan (financial liability) is based on level 2 measurement procedures (see notes 13 and 17).&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Loss per common share is calculated by&#13;dividing the loss of the period by the weighted average number of common shares outstanding during the period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has granted warrants under&#13;certain loan agreements (see note 17) and options under share-based payment programs (see note 16) which potentially have a dilutive&#13;effect; no instruments actually had a dilutive effect.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the consolidated financial&#13;statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application&#13;of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these&#13;estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Estimates and underlying assumptions are&#13;reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised&#13;and in any future periods affected.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In preparing these financial statements,&#13;the critical judgments made by management in applying the Company's accounting policies resulted in the following accounting estimates:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0pt"&gt;&lt;/td&gt;&lt;td style="width: 35.45pt"&gt;&lt;font style="font-size: 8pt"&gt;(i)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Share-based payments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-indent: 0in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of stock options issued&#13;by Affimed N.V. is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input&#13;parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends,&#13;the risk-free interest rate and the time to maturity of the option. The fair value of share-based equity-settled compensation plans&#13;is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity.&#13;The number of stock options expected to vest is estimated at each measurement date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0pt"&gt;&lt;/td&gt;&lt;td style="width: 35.45pt"&gt;&lt;font style="font-size: 8pt"&gt;(ii)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Revenue recognition &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-indent: 0in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Elements of consideration in collaboration&#13;and license agreements are non-refundable up-front research funding payments, technology access fees and milestone payments. Generally,&#13;the Company has continuing performance obligations and therefore up-front payments are deferred and the related revenues recognized&#13;in the period of the expected performance. Technology access fees are generally deferred and recognized over the expected term&#13;of the research service agreement on a straight-line basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company estimates that the achievement&#13;of a milestone reflects a stage of completion under the terms of the agreements and recognizes revenue when a milestone is achieved.&#13;If the research service is cancelled due to technical failure, the remaining deferred revenues from upfront payments are recognized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt/120% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;&#13;&lt;td style="width: 0pt"&gt;&lt;/td&gt;&lt;td style="width: 35.45pt"&gt;&lt;font style="font-size: 8pt"&gt;(iii)&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Accrued expenses&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company estimates its accrued expenses&#13;reviewing quotations and contracts, identifying services that have been performed on its behalf, estimating the level of service&#13;performed and the associated cost incurred for the service when Affimed has not yet been invoiced or otherwise notified of the&#13;actual cost. The majority of Affimed&amp;#8217;s service providers invoice monthly in arrears for services performed or when contractual&#13;milestones are met. Affimed makes estimates of its accrued expenses as of each balance sheet date in the consolidated financial&#13;statements based on facts and circumstances known to it at that time. Affimed periodically confirms the accuracy of its estimates&#13;with the service providers and makes adjustments as necessary.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;No new accounting standards adopted in&#13;2017 had a material impact on Affimed&amp;#8217;s consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="From2017-01-01to2017-12-31">&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following new standards and amendments&#13;to standards are effective for annual periods beginning after December 31, 2017, and have not been applied in preparing these consolidated&#13;financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 45%; padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Standard / Amendment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 45%; padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Effective Date &lt;sup&gt;1&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;IFRS 15 Revenue from Contracts with Customers&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;IFRS 9 Financial Instruments (2014)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;IFRS 16 Leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Clarifications to IFRS 15 Revenue from Contracts with Customers&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Amendments&amp;#160;to&amp;#160;IFRS&amp;#160;2:&amp;#160;Classification&amp;#160;and&amp;#160;Measurement&amp;#160;of&amp;#160;Share-based&amp;#160;Payment&amp;#160;Transactions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Annual Improvements to IFRS Standards 2014-2016 Cycle (IFRS 1, IAS 28)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Amendments to IFRS 9: Prepayment Features with Negative Compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Amendments&amp;#160;to&amp;#160;IAS&amp;#160;28:&amp;#160;Long-term&amp;#160;Interests&amp;#160;in&amp;#160;Associates&amp;#160;and&amp;#160;Joint&amp;#160;Ventures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Annual Improvements to IFRS Standards 2015-2017 Cycle&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/120% Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;sup&gt;1&lt;/sup&gt; Shall apply for periods beginning&#13;on or after the effective date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company assessed the potential impact&#13;that IFRS 9, 15 or 16 will have on its consolidated financial statements. The other amended standards are not expected to have&#13;a significant effect on the consolidated financial statements of the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;IFRS 9 (Financial Instruments)&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Classification&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The standard contains a new classification&#13;and measurement approach for financial instruments that reflects the business model in which assets are managed and their cash&#13;flow characteristics. Based on the new measurement requirements, Affimed will recognize its preferred shares in Amphivena at fair&#13;value and will increase retained earnings by approximately &amp;#8364;7 million before taxes as of January 1, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Hedge Accounting&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The new hedge accounting requirements will&#13;not have an impact on the consolidated financial statements as the Company does not have contracts or transactions which qualify&#13;for hedge accounting.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Impairment&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The new introduced impairment rules replace&#13;the &amp;#8216;incurred loss&amp;#8217; model in IAS 39 with a forward looking &amp;#8216;expected credit loss&amp;#8217; (&amp;#8220;ECL&amp;#8221;) model.&#13;This requires considerable judgement as to how changes in economic factors affect ECLs, which will be determined on a probability-weighted&#13;basis. Under IFRS 9, the Company has decided to measure loss allowances on the following basis:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; line-height: 107%"&gt;&lt;font style="font: 8pt/120% Arial, Helvetica, Sans-Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Cash and cash equivalents and financial assets: The Company determines the counterparties&amp;#8217; 12-month ECLs that result from possible default events within the 12 months after the reporting date based on the probability of default according to the Bloomberg database. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; line-height: 107%"&gt;&lt;font style="font: 8pt/120% Arial, Helvetica, Sans-Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/120% Times New Roman, Times, Serif"&gt;Trade receivables: The Company determines the counterparties&amp;#8217; lifetime ECLs that result from all possible default events over the expected life of a financial instrument based on an estimated rating and corresponding probability of default rates according to the Bloomberg database. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Based on this methodology, incurred losses&#13;on cash and cash equivalents and on trade and other receivables as of December 31, 2017 would have no material impact on the consolidated&#13;financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;IFRS 15 (Revenue from contracts with customers)&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;IFRS 15 (Revenue from contracts with customers)&#13;establishes a comprehensive framework for determining whether, how much and when revenue is recognized. It replaces existing revenue&#13;recognition guidance, including IAS 18 Revenue, IAS 11 Construction Contracts and IFRIC 13 Customer Loyalty Programs. IFRS 15 has&#13;not been applied yet by Affimed but application will be required for periods beginning on or after January 1, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Affimed has finalized the assessment of&#13;all contracts with customers and IFRS 15 has no impact on the revenue recognition policy and revenue from current collaboration&#13;and service agreements which is recognized according to the stage of completion.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;IFRS 16 (Leases)&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The new standard specifies how to recognize,&#13;measure, present and disclose lease agreements. The standard provides a single lessee accounting model, requiring lessees to recognize&#13;assets and liabilities for all leases unless the lease term is 12 months or less or the underlying asset has a low value. Affimed&#13;will be required to recognize &amp;#8220;right-of-use&amp;#8221; assets related to its premises rented and certain equipment leased. During&#13;the next year, the Company will gather and update information related to leases, assess extension and termination options as well&#13;as possible exemptions and identify the appropriate discount rate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"&gt;&amp;#160;&lt;/p&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <AFMD:SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 45%; padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;Standard / Amendment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 45%; padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;Effective Date &lt;sup&gt;1&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: center; line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;IFRS 15 Revenue from Contracts with Customers&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;IFRS 9 Financial Instruments (2014)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;IFRS 16 Leases&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;Clarifications to IFRS 15 Revenue from Contracts with Customers&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;Amendments&amp;#160;to&amp;#160;IFRS&amp;#160;2:&amp;#160;Classification&amp;#160;and&amp;#160;Measurement&amp;#160;of&amp;#160;Share-based&amp;#160;Payment&amp;#160;Transactions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;Annual Improvements to IFRS Standards 2014-2016 Cycle (IFRS 1, IAS 28)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;January 1, 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;Amendments to IFRS 9: Prepayment Features with Negative Compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;Amendments&amp;#160;to&amp;#160;IAS&amp;#160;28:&amp;#160;Long-term&amp;#160;Interests&amp;#160;in&amp;#160;Associates&amp;#160;and&amp;#160;Joint&amp;#160;Ventures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 5.4pt; text-align: justify; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;Annual Improvements to IFRS Standards 2015-2017 Cycle&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 107%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-left: 11.65pt; text-align: center; line-height: 107%"&gt;&lt;font style="font: 8pt/106% Times New Roman, Times, Serif"&gt;January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/120% Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;sup&gt;1&lt;/sup&gt; Shall apply for periods beginning&#13;on or after the effective date.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</AFMD:SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock>
    <AFMD:SummaryOfGeographicInformationTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font: bold 8pt Times New Roman, Times, Serif"&gt;Revenues:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Germany&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;125&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;80&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Europe&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;711&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,397&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,236&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 3.5pt"&gt;USA&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;6,725&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;4,911&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;694&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;7,562&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;6,314&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;2,010&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: bold 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Non-current assets as of December 31:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Germany&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;618&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;957&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Czech Republic&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;259&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;221&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;877&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,178&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfGeographicInformationTableTextBlock>
    <AFMD:SummaryOfResearchAndDevelopmentExpensesTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Third-party services&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;15,386&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;20,170&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;12,299&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Personnel expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;3,637&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;6,648&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;5,639&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Legal, consulting and patent expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;902&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;758&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;890&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Cost of Materials&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;902&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,028&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;994&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Amortization and depreciation&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;308&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;322&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;309&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Operating lease expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;267&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;297&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;345&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;606&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;957&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;22,008&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;30,180&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;21,489&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfResearchAndDevelopmentExpensesTableTextBlock>
    <AFMD:SummaryOfGeneralAndAdministrativeExpensesTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Personnel expenses&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;3,658&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;4,729&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;4,521&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Legal, consulting and audit fees&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;2,468&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;2,210&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,945&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Operating lease expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;89&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;111&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;126&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,333&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,273&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,394&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;7,548&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;8,323&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;7,986&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfGeneralAndAdministrativeExpensesTableTextBlock>
    <AFMD:SummaryOfEmployeeBenefitsTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Wages and salaries&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;5,066&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;7,445&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;7,475&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Social security costs&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;583&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;807&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;931&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;5,649&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;8,252&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;8,406&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfEmployeeBenefitsTableTextBlock>
    <AFMD:SummaryOfFinanceIncomeAndFinanceCostsTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2015&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; text-align: left; padding-left: 3.5pt"&gt;Interest Perceptive Loan Agreement (see note 17)&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(703&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;(762&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Other finance cost Perceptive Loan Agreement (see note 17)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(242&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Interest SVB Loan Agreement (see note 17)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(41&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(690&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Foreign exchange differences&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,808&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;691&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,378&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Interest on certificates of deposit with maturities of more than three months (see note 14)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Other finance income/finance costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Finance income/costs - net&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,104&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(230&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,983&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfFinanceIncomeAndFinanceCostsTableTextBlock>
    <AFMD:SummaryOfIncomeTaxReconciliationTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Loss before tax&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(20,239&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(32,274&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(30,243&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Income tax benefit at tax rate of 29.825 %&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;6,036&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;9,626&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;9,020&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Adjustments due to impairment of deferred tax assets&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(6,251&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(8,747&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(9,036&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Permanent differences&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;199&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(948&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(93&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Adjustments for local tax rates&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;18&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;195&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Non deductible expenses&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;163&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;154&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;16&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Other&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(165&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(82&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Income taxes&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;58&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;20&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfIncomeTaxReconciliationTableTextBlock>
    <AFMD:SummaryOfAssumptionsOfOptionsGrantedTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 3.5pt"&gt;Fair value at grant date&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.99&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;Share price at grant date&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;Exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Expected life&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.32&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.23&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfAssumptionsOfOptionsGrantedTableTextBlock>
    <AFMD:SummaryOfFairValueOfAssetsPledgedTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center"&gt;Book value as of December 31, 2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="text-align: center"&gt;Book value as of December 31, 2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt; padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Consolidated financial statements&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;thereof assets pledged&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Consolidated financial statements&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;thereof assets pledged&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font-size: 11pt; padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 40%; text-align: left; padding-left: 3.5pt"&gt;Leasehold improvements and equipment&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;822&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;542&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,113&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;891&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;Inventories&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;197&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;219&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Trade and other receivables&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,217&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,102&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;328&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Other assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;516&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;292&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="text-align: left; padding-left: 3.5pt"&gt;Financial assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,487&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;35,407&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;34,674&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;39,837&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38,726&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-size: 11pt; padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48,684&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,096&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,093&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfFairValueOfAssetsPledgedTableTextBlock>
    <AFMD:SummaryOfEarningsPerShareTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(20,239&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(32,216&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(30,223&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Weighted number of common shares outstanding&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;28,477,438&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;33,259,505&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;43,746,073&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;Loss per share in &amp;#8364; per share&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(0.71&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(0.97&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;(0.69&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfEarningsPerShareTableTextBlock>
    <AFMD:SummaryOfFutureMinimumLeasePaymentObligationsTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-size: 11pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2016&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 3.5pt"&gt;Within one year&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;700&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;470&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Between one and five years&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;541&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;363&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font-size: 11pt; padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,241&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;833&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfFutureMinimumLeasePaymentObligationsTableTextBlock>
    <AFMD:SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Short-term employee benefits&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,633&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,879&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,538&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Termination benefits&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;430&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 3.5pt"&gt;Share-based payments&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,474&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;2,292&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;1,379&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;3,107&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;4,601&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;2,917&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock>
    <AFMD:SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5" style="font: 8pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Outstanding balances&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;December 31, 2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 56%; font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Thomas Hecht&lt;/td&gt;&lt;td style="width: 8%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;23&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Richard Stead&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;14&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Berndt Modig&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;8&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Ferdinand Verdonck&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;10&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;10&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Ulrich Grau&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;17&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;17&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Bernhard Ehmer&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;11&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;10&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;Jens-Peter Marschner&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;2&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock>
    <AFMD:SummaryOfExchangeRatesTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2016&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;2017&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;CZK or USD/EUR&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;CZK or USD/EUR&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;CZK or USD/EUR&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="width: 46%; font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;CZK - Average Rate&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0.03666&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0.03699&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%; font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 11%; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0.03799&lt;/td&gt;&lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;CZK - Spot rate&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0.03701&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0.03701&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0.03916&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="padding-left: 3.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; padding-left: 3.5pt"&gt;USD - Average Rate&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0.90190&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0.90404&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0.88519&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 3.5pt"&gt;USD - Spot rate&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0.91853&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0.94868&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;0.83382&lt;/td&gt;&lt;td style="font: 8pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</AFMD:SummaryOfExchangeRatesTableTextBlock>
    <ifrs-full:TitleOfNewIFRS contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment1Member">IFRS 15 Revenue from Contracts with Customers</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:TitleOfNewIFRS contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment2Member">IFRS 9 Financial Instruments (2014)</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:TitleOfNewIFRS contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment3Member">IFRS 16 Leases</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:TitleOfNewIFRS contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment4Member">Clarifications to IFRS 15 Revenue from Contracts with Customers</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:TitleOfNewIFRS contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment5Member">Amendments&#160;to&#160;IFRS&#160;2:&#160;Classification&#160;and&#160;Measurement&#160;of&#160;Share-based&#160;Payment&#160;Transactions</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:TitleOfNewIFRS contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment6Member">Annual Improvements to IFRS Standards 2014-2016 Cycle (IFRS 1, IAS 28)</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:TitleOfNewIFRS contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment7Member">Amendments to IFRS 9: Prepayment Features with Negative Compensation</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:TitleOfNewIFRS contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment8Member">Amendments&#160;to&#160;IAS&#160;28:&#160;Long-term&#160;Interests&#160;in&#160;Associates&#160;and&#160;Joint&#160;Ventures</ifrs-full:TitleOfNewIFRS>
    <ifrs-full:TitleOfNewIFRS contextRef="From2017-01-01to2017-12-31_custom_StandardAmendment9Member">Annual Improvements to IFRS Standards 2015-2017 Cycle</ifrs-full:TitleOfNewIFRS>
    <AFMD:OperatingLossCarryforwardsForCorporateIncomeTaxPurposes contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">146800000</AFMD:OperatingLossCarryforwardsForCorporateIncomeTaxPurposes>
    <AFMD:OperatingLossCarryforwardsForCorporateIncomeTaxPurposes contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">117400000</AFMD:OperatingLossCarryforwardsForCorporateIncomeTaxPurposes>
    <AFMD:OperatingLossCarryforwardsForTradeTaxPurposes contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">146400000</AFMD:OperatingLossCarryforwardsForTradeTaxPurposes>
    <AFMD:OperatingLossCarryforwardsForTradeTaxPurposes contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">117000000</AFMD:OperatingLossCarryforwardsForTradeTaxPurposes>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="From2017-01-01to2017-12-31_custom_Esop2014Member" unitRef="Shares" decimals="INF">1436075</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="From2016-01-01to2016-12-31_custom_Esop2014Member" unitRef="Shares" decimals="INF">1778095</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="From2017-01-01to2017-12-31_custom_Esop2014Member" unitRef="Shares" decimals="INF">399552</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="From2016-01-01to2016-12-31_custom_Esop2014Member" unitRef="Shares" decimals="INF">83750</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="From2017-01-01to2017-12-31" unitRef="EUR" decimals="-3">1943000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="From2016-01-01to2016-12-31" unitRef="EUR" decimals="-3">3545000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="From2015-01-01to2015-12-31" unitRef="EUR" decimals="-3">2220000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="From2017-01-01to2017-12-31_custom_ResearchAndDevelopmentMember" unitRef="EUR" decimals="-3">522000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="From2016-01-01to2016-12-31_custom_ResearchAndDevelopmentMember" unitRef="EUR" decimals="-3">1178000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="From2015-01-01to2015-12-31_custom_ResearchAndDevelopmentMember" unitRef="EUR" decimals="-3">611000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="From2017-01-01to2017-12-31_custom_GeneralAndAdministrativeMember" unitRef="EUR" decimals="-3">1421000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="From2016-01-01to2016-12-31_custom_GeneralAndAdministrativeMember" unitRef="EUR" decimals="-3">2367000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="From2015-01-01to2015-12-31_custom_GeneralAndAdministrativeMember" unitRef="EUR" decimals="-3">1609000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="From2017-01-01to2017-12-31_custom_SupervisoryBoardDirectorsMember" unitRef="EUR" decimals="-3">144000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="From2016-01-01to2016-12-31_custom_SupervisoryBoardDirectorsMember" unitRef="EUR" decimals="-3">381000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="From2015-01-01to2015-12-31_custom_SupervisoryBoardDirectorsMember" unitRef="EUR" decimals="-3">478000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:OtherCurrentPayables contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">3083000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">973000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:LongtermDeposits contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">9500000</ifrs-full:LongtermDeposits>
    <AFMD:ConvertibleNoteAndWarrants contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">300000</AFMD:ConvertibleNoteAndWarrants>
    <AFMD:MaximumExposureToForeignCurrencyRisk contextRef="AsOf2017-12-31" unitRef="EUR" decimals="-3">18768000</AFMD:MaximumExposureToForeignCurrencyRisk>
    <AFMD:MaximumExposureToForeignCurrencyRisk contextRef="AsOf2016-12-31" unitRef="EUR" decimals="-3">18974000</AFMD:MaximumExposureToForeignCurrencyRisk>
    <AFMD:KeyManagementPersonnelCompensationForServices contextRef="From2016-01-01to2016-12-31_custom_UlrichGrauMember" unitRef="EUR" decimals="-3">86000</AFMD:KeyManagementPersonnelCompensationForServices>
    <AFMD:KeyManagementPersonnelCompensationForServices contextRef="From2017-01-01to2017-12-31_custom_JensPeterMarschnerMember" unitRef="EUR" decimals="-3">11000</AFMD:KeyManagementPersonnelCompensationForServices>
    <AFMD:KeyManagementPersonnelCompensationForServices contextRef="From2016-01-01to2016-12-31_custom_JensPeterMarschnerMember" unitRef="EUR" decimals="-3">29000</AFMD:KeyManagementPersonnelCompensationForServices>
    <AFMD:KeyManagementPersonnelCompensationForServices contextRef="From2017-01-01to2017-12-31_custom_SupervisoryBoardDirectorsMember" unitRef="EUR" decimals="-3">375000</AFMD:KeyManagementPersonnelCompensationForServices>
    <AFMD:KeyManagementPersonnelCompensationForServices contextRef="From2016-01-01to2016-12-31_custom_SupervisoryBoardDirectorsMember" unitRef="EUR" decimals="-3">350000</AFMD:KeyManagementPersonnelCompensationForServices>
    <AFMD:KeyManagementPersonnelCompensationForServices contextRef="From2015-01-01to2015-12-31_custom_SupervisoryBoardDirectorsMember" unitRef="EUR" decimals="-3">296000</AFMD:KeyManagementPersonnelCompensationForServices>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-02" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-0" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-1" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-2" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-3" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-4" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-5" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-6" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-7" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-8" xlink:label="Foot-01_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-01_loc" xlink:to="Footnote-01" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">Shall apply for periods beginning on or after the effective date.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">Issue of 3,341 shares</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>